Quarterly Report (10-q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q


(Mark One)
		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

X		For the quarterly period ended December 31, 2015

		TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from:		to


Commission File No. 001-14949

Implant Sciences Corporation

Massachusetts		042837126
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

500 Research Drive, Unit 3, Wilmington, Massachusetts		01887
(Address of principal executive offices)		(Zip Code)

(978) 752-1700
(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


☐ Large Accelerated Filer	☐ Accelerated Filer
☐ Non-accelerated Filer	☒ Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of February 5, 2016, there were 78,805,620 shares of the registrant’s Common Stock outstanding. As of December 31, 2015, the last business day of the registrant’s most recent completed second quarter, the aggregate market value of the registrant’s Common Stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) was $39,582,000 based on the last sale price as reported by the Over-The-Counter-Bulletin-Board on such date.

IMPLANT SCIENCES CORPORATION

TABLE OF CONTENTS


		Page
PART I	FINANCIAL INFORMATION
Item 1.	Condensed Consolidated Financial Statements
	Condensed Consolidated Balance Sheets as of December 31, 2015 (unaudited) and June 30, 2015 (audited)	3
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended December 31, 2015 and 2014 (unaudited)	4
	Condensed Consolidated Statements of Cash Flows for the six months ended December 31, 2015 and 2014 (unaudited)	5
	Notes to Condensed Consolidated Financial Statements (unaudited)	6–24
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	25-33
Item 4.	Controls and Procedures	33-34
PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	34-35
Item 1A.	Risk Factors	35
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	36
Item 6.	Exhibits	37


Implant Sciences Corporation
Condensed Consolidated Balance Sheets
(In thousands except share and per share amounts)
	December 31, 2015	June 30, 2015
	(Unaudited)	(Audited)
ASSETS
Current assets:
Cash and cash equivalents	$ 776	$ 1,985
Restricted cash and investments	367	367
Accounts receivable-trade, net of allowances of $5 and $47, respectively	6,116	872
Inventories, net	6,723	5,244
Prepaid expenses and other current assets	491	946
Total current assets	14,473	9,414
Property and equipment, net	841	880
Other non-current assets	98	98
Total assets	$ 15,412	$ 10,392
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Senior secured promissory note – BAM	$ 20,000	$ 20,000
Senior secured convertible promissory note – Montsant Partners	3,184	3,184
Senior secured promissory note – DMRJ	1,000	1,000
Second senior secured convertible promissory note – DMRJ	12,000	12,000
Third senior secured convertible promissory note - DMRJ	12,000	12,000
Line of credit – DMRJ	16,862	16,662
Current maturities of obligations under capital lease	26	45
Accrued expenses	24,759	17,080
Accounts payable	4,797	2,855
Deferred revenue	1,466	3,454
Total current liabilities	96,094	88,280
Long-term liabilities:
Long-term obligations under capital lease, net of current maturities	15	20
Accrued expenses, net of current	-	48
Deferred revenue, net of current	355	221
Total long-term liabilities	370	289
Total liabilities	96,464	88,569
Commitments and contingencies (Note 16)
Stockholders' deficit:
Common stock; $0.001 par value; 200,000,000 shares authorized; 78,699,165 and 78,688,620 shares issued and outstanding at December 31, 2015 and 75,113,665 and 75,103,120 shares issued and outstanding at June 30, 2015	79	75
Preferred stock; no stated value; 5,000,000 shares authorized
Series G Convertible Preferred Stock, no stated value; 650,000 shares authorized, no shares issued and outstanding	-	-
Series H Convertible Preferred Stock; no stated value; 15,000 shares authorized, no shares issued and outstanding	-	-
Series I Convertible Preferred Stock; no stated value; 15,000 shares authorized, no shares issued and outstanding	-	-
Series J Convertible Preferred Stock; no stated value; 6,000 shares authorized, no shares issued and outstanding	-	-
Additional paid-in capital	113,566	112,613
Accumulated deficit	(193,653)	(189,429)
Deferred compensation	(993)	(1,366)
Other comprehensive income	22	3
Treasury stock, 10,545 common shares, at cost	(73)	(73)
Total stockholders’ deficit	(81,052)	(78,177)
Total liabilities and stockholders’ deficit	$ 15,412	$ 10,392

The accompanying notes are an integral part of these condensed consolidated financial statements.


Implant Sciences Corporation
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands except share and per share amounts)
(Unaudited)

	For the Three Months Ended December 31,		For the Six Months Ended December 31,
	2015	2014	2015	2014
Revenues	$ 10,292	$ 2,141	$ 24,685	$ 4,010
Cost of revenues	6,439	1,777	14,575	3,028
Gross margin	3,853	364	10,110	982
Operating expenses:
Research and development	901	1,288	1,984	2,572
Selling, general and administrative	3,718	3,195	7,256	5,870
Total operating expenses	4,619	4,483	9,240	8,442
(Loss) income from operations	(766)	(4,119)	870	(7,460)
Other income (expense), net:
Interest expense	(2,547)	(2,125)	(5,094)	(4,159)
Net loss	(3,313)	(6,244)	(4,224)	(11,619)

Other comprehensive loss net of tax:
Foreign currency translation adjustments	(9)	4	(19)	1
Comprehensive loss	$ (3,322)	$ (6,240)	$ (4,243)	$ (11,618)

Net loss per share, basic and diluted	$ (0.04)	$ (0.09)	$ (0.05)	$ (0.17)

Weighted average shares used in computing net loss per common share, basic and diluted	78,528,620	70,938,120	77,367,787	67,842,872

The accompanying notes are an integral part of these condensed consolidated financial statements.


Implant Sciences Corporation
Condensed Consolidated Statements of Cash Flows
(In thousands)
*(Unaudited)*

	For the Six Months Ended December 31,
	2015	2014
Cash flows from operating activities:
Net loss	$ (4,224)	$ (11,619)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	104	81
Bad debt expense	(7)	46
Stock-based compensation expense	668	1,227
Warrants issued to non-employees	43	241
Common stock issued to consultants	331	68
Changes in assets and liabilities:
Accounts receivable	(5,237)	(416)
Inventories	(1,479)	170
Prepaid expenses and other current assets	455	37
Accounts payable	1,942	(134)
Accrued expenses	7,885	3,125
Deferred revenue	(1,854)	1,279
Net cash used in operating activities	(1,373)	(5,895)

Cash flows from investing activities:
Purchases of property and equipment	(65)	(314)
Net cash used in investing activities	(65)	(314)

Cash flows from financing activities:
Proceeds from common stock issued in connection with exercise of stock options and common stock purchase warrants	34	261
Principal repayments of long-term debt and capital lease obligations	(24)	(23)
Net borrowings on line of credit	200	5,605
Net cash provided by financing activities	210	5,843
Effect of exchange rate changes on cash and cash equivalents	19	1
Net change in cash and cash equivalents	(1,209)	(365)
Cash and cash equivalents at beginning of period	1,985	391
Cash and cash equivalents at end of period	$ 776	$ 26

Supplemental Disclosure of Cash Flow Information:
Interest paid	$ 5	$ 1,619
Non-cash Financing Activity:
Conversions of senior secured convertible promissory note interest to common shares	$ 245	$ 604
Common stock issued to consultants	331	68

The accompanying notes are an integral part of these condensed consolidated financial statements.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Description of Business, Liquidity and Going Concern

Implant Sciences Corporation provides systems and sensors for the homeland security market and related industries. We have developed and acquired technologies using ion mobility spectrometry to develop a product line for use in trace explosives and narcotics detection. We currently market and sell our existing trace explosives and narcotics detector products while continuing to make significant investments in developing the next generation of these products.

Liquidity, Going Concern and Management’s Plans

On December 10, 2008, we entered into a note and warrant purchase agreement with DMRJ Group LLC (“DMRJ”) pursuant to which we issued a senior secured convertible promissory note in the principal amount of $5,600,000 and a warrant to purchase 1,000,000 shares of our common stock. We have entered into a series of amendments, waivers and modifications with DMRJ. On March 19, 2015, we amended our credit agreements with DMRJ pursuant to which, amongst other matters, we extended the maturity date of all of our indebtedness from March 31, 2015 to March 31, 2016.

On May 4, 2015, we entered into an assignment agreement with DMRJ and Montsant Partners, LLC, wherein DMRJ assigned its rights, title and interest in the senior secured promissory note dated December 10, 2008 and appointed DMRJ as its collateral agent under the promissory note agreement. The note matures on March 31, 2016. DMRJ and Montsant Partners, LLC are funds managed by Platinum Partners Value Arbitrage Fund LP.

On March 19, 2014, we entered into a note purchase agreement with a group of institutional investors and BAM Administrative Services LLC (“BAM”), an administrative agent for the investors, pursuant to which we issued senior secured promissory notes in the aggregate principal amount of $20,000,000. The notes bear interest at 16% per annum and mature on March 31, 2016. We used all of the proceeds from the sale of the notes to repay (i) $17,624,000 of our outstanding indebtedness to DMRJ under revolving promissory note (ii) $1,809,000 of interest outstanding under that facility and (iii) $567,000 of interest outstanding under our senior secured convertible promissory note (see Note 13).

On December 11, 2015, we entered into an Accounts Receivable Purchase Agreement (the “Purchase Agreement”) with Republic Capital Access, LLC (“RCA”), pursuant to which we may sell eligible accounts receivables relating to U.S. government prime contracts or subcontracts (as defined in the Purchase Agreement, “Eligible Receivables”) to RCA. The total amount of Eligible Receivables that we may sell to RCA is subject to a maximum limit of $2,000,000 of outstanding receivables (the “Maximum Amount”) at any given time. The Purchase Agreement terminates on November 30, 2016.

Despite our current sales, expense and cash flow projections and $3,084,000 in cash available from our line of credit with DMRJ, at February 5, 2016, to fund our operations and continue the development, commercialization and marketing of our products will require that we extend our note agreements with DMRJ, BAM and Monstant. There can be no assurance that DMRJ will continue to make advances under our revolving line of credit. Our failure to achieve our projections and/or obtain sufficient additional capital on acceptable terms would have a material adverse effect on our liquidity and operations and could require us to file for protection under bankruptcy laws.

Our common stock was delisted by the NYSE Amex LLC in June 2009 as a result of our failure to comply with certain continued listing requirements. Our common stock has been quoted on the OTC Bulletin Board since May 2009 and is also quoted on the OTC Markets Group’s OTCQB tier under the symbol “IMSC”. We believe that trading ‘over the counter’ has limited our stock’s liquidity and has impaired our ability to raise capital.

In addition, while we strive to bring new products to market, we are subject to a number of risks similar to the risks faced by other technology-based companies, including risks related to: (a) our dependence on key individuals and collaborative research partners; (b) competition from substitute products and larger companies; (c) our ability to develop and market commercially usable products and obtain regulatory approval for our products under development; and (d) our ability to obtain substantial additional financing necessary to adequately fund the development, commercialization and marketing of our products. For the six months ended December 31, 2015, we reported a net loss of approximately $4,224,000 and approximately used $1,373,000 in cash for operations. As of December 31, 2015, the Company had an accumulated deficit of approximately $193,653,000 and a working capital deficit of approximately $81,621,000. Management continually evaluates operating expenses and cash flow from operations. Failure of the Company to achieve its projections will require that we seek additional financing or discontinue operations.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2015, our obligations to DMRJ under each of the three promissory notes and a revolving line of credit approximated $12,000,000, $12,000,000, $1,000,000 and $16,862,000, respectively. Further, as of December 31, 2015, our obligation to DMRJ for accrued interest under these instruments approximated $14,559,000 and is included in accrued expenses in the condensed consolidated financial statements.

As of December 31, 2015, our obligations to Montsant under a promissory note approximated $3,184,000. Further, as of December 31, 2015, our obligation to Montsant for accrued interest under this instrument approximated $1,860,000 and is included in accrued expenses in the condensed consolidated financial statements.

On September 24, 2015, Montsant converted $245,000 of the accrued interest owed by us under a promissory note into 3,062,500 shares of our common stock, at an adjusted conversion price of $0.08 per share.

As of December 31, 2015, our obligations under the senior secured promissory notes for which BAM is the agent were $20,000,000. Further, as of December 31, 2015, our obligation under such notes for accrued interest amounted to approximately $1,690,000 and is included in accrued expenses in the condensed consolidated financial statements.

As of February 5, 2016, our obligations to DMRJ under each of the three promissory notes and a revolving line of credit approximated $12,000,000, $12,000,000, $1,000,000 and $16,862,000, respectively. Further, as of February 5, 2016, our obligation to DMRJ for accrued interest under these instruments approximated $15,187,000.

As of February 5, 2016, our obligations to Montsant under a promissory note approximated $3,184,000. Further, as of February 5, 2016, our obligation to Montsant for accrued interest under this instrument approximated $1,907,000.

As of February 5, 2016, our obligations under the senior secured promissory notes for which BAM is the agent were $20,000,000. Further, as of February 5, 2016, our obligation under such notes for accrued interest amounted to approximately $2,010,000.

These conditions raise substantial doubt as to our ability to continue as a going concern.

Our ability to comply with our debt covenants in the future depends on our ability to generate sufficient sales and to control expenses, and will require that we seek additional capital through private financing sources. There can be no assurances that we will achieve our forecasted financial results or that we will be able to raise additional capital to operate our business. Any such failure would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely. Further, upon the occurrence of an event of default under certain provisions of our credit agreements, we could be required to pay default rate interest equal to the lesser of 2.5% per month and the maximum applicable legal rate per annum on the outstanding principal balance outstanding. The failure to refinance or otherwise negotiate further extensions of our obligations to our secured lenders would have a material adverse impact on our liquidity and financial condition and could force us to curtail or discontinue operations entirely and/or file for protection under bankruptcy laws.

Based on current sales, operating expense and cash flow projections, and the cash available from our line of credit, management believes there are plans in place to sustain operations, provided that our credit facilities are extended. These plans depend on a substantial increase in sales of our handheld trace explosives detector product and our desktop explosives and narcotics trade detector product and on the extension of the maturity date of our credit facilities with DMRJ, BAM and Montsant. However, there can be no assurances that sales will materialize as forecasted, and/or that management will be successful in refinancing or extending our obligations to our secured lenders, which mature on March 31, 2016. To further sustain us, improve our cash position, and enable us to grow while reducing debt, management plans to continue to seek additional capital through private financing sources. However, there can be no assurance that management will be successful in executing these plans. Management will continue to closely monitor and attempt to control our costs and actively seek needed capital through sales of our products, equity infusions, government grants and awards, strategic alliances, and through our lending institutions.

We have suffered recurring losses from operations. Our consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

There can be no assurances that our forecasted results will be achieved or that we will be able to raise additional capital necessary to operate our business. These conditions raise substantial doubt about our ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

Security product sales tend to have a long sales cycle, and are often subject to export controls. In an effort to identify new opportunities and stimulate sales, we hired additional sales personnel during fiscal 2013 that have specific industry experience and have retained new distributors. However, there can be no assurance that these efforts will increase revenue.

We have a history of being active in submitting proposals for government sponsored grants and contracts and successful in being awarded grants and contracts from government agencies. However, we have recorded no revenues from government grants or contracts, due to the expiration of several contracts and our inability to secure new contracts. Management will continue to pursue these grants and contracts to support our research and development efforts primarily in the areas of trace explosives detection.

On October 16, 2014, the U.S. Department of Homeland Security (“DHS”) selected our proposal to develop next generation explosives trace detection screening systems for funding under a statement of work. The project, pending successful negotiations, is potentially worth up to approximately $2 million. Subject to successful conclusion of negotiations with the DHS, we expect the project to commence in the fourth of quarter of fiscal 2016.

We are currently expending significant resources to develop the next generation of our current products and to develop new products. We will require additional funding in order to continue the advancement of the commercial development and manufacturing of the explosives detection system. We will attempt to obtain such financing by: (i) government grants, (ii) private financing, or (iii) strategic partnerships. However, there can be no assurance that we will be successful in our attempts to raise such additional financing.

We will require substantial funds for further research and development, regulatory approvals, and the marketing of our explosives detection products. Our working capital requirements depend on numerous factors, including but not limited to the progress of our research and development programs; the cost of filing, prosecuting, defending and enforcing any intellectual property rights; competing technological and market developments; changes in our development of commercialization activities and arrangements; and the hiring of additional personnel, and acquiring capital equipment. Our failure to achieve our projections and/or obtain sufficient additional capital on acceptable terms would have a material adverse effect on our liquidity and operations and could require us to file for protection under bankruptcy laws.

Interim Financial Statements and Basis of Presentation

Principles of Consolidation

The accompanying condensed consolidated financial statements include our operations in Massachusetts, our former facilities in California and Shanghai, China, and those of our wholly-owned subsidiaries. On March 25, 2015, our Board of Directors approved restructuring actions to better align costs with current and future geographic revenue sources and to improve efficiencies. Our San Diego, CA advanced technology office was relocated to our Wilmington, MA facility and our Shanghai office was closed. All intercompany transactions and accounts have been eliminated in consolidation.

Accounting Principles

The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments (consisting only of normal recurring adjustments), which we consider necessary for a fair presentation of the financial position at such date and of the operating results and cash flows for the periods presented. The results of operations and cash flows for the six months ended December 31, 2015 may not necessarily be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The balance sheet at December 31, 2015 has been derived from our audited consolidated financial statements at that date, but does not include all of the information and notes required by U.S. GAAP for complete financial statements.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The information contained in this Form 10-Q should be read in conjunction with our audited financial statements, included in our Form 10-K, as of and for the year ended June 30, 2015.

Use of Accounting Estimates

The preparation of these financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Some of the more significant estimates include allowance for doubtful accounts, allowance for sales returns, inventory valuation, warranty reserves, stock-based compensation and long-lived assets. Management's estimates are based on the facts and circumstances available at the time estimates are made, past historical experience, risk of loss, general economic conditions and trends and management's assessments of the probable future outcome of these matters. Consequently, actual results could differ from such estimates.

Significant accounting policies are described in Note 2 to the consolidated financial statements included in Item 7 of our Form 10-K for the fiscal year ended June 30, 2015.

Foreign Currency Translation

The assets and liabilities of our Shanghai representative office were translated into U.S. dollars at current exchange rates as of the balance sheet date; expenses were translated at average monthly exchange rates. Net unrealized translation gains or losses associated with the Shanghai office were recorded directly to other comprehensive income. Realized gains and losses from foreign currency transactions were not material for any of the periods presented. We had short-term inter-company receivables from our Shanghai office which were adjusted each period for changes in foreign currency exchange rates with a corresponding entry recorded as a component of the condensed consolidated statement of operations and comprehensive loss.

Recent Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), which supersedes the revenue recognition requirements in ASC 605, “Revenue Recognition”. The FASB issued ASU 2014-09 to clarify the principles for recognizing revenue and to develop a common revenue standard for U.S. GAAP and International Financial Reporting Standards. The core principle of this updated guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The new rule also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim reporting periods therein, which is effective for our fiscal year beginning July 1, 2018, the first day of our 2019 fiscal year. We are currently evaluating the impact of this accounting guidance and do not expect any significant impact on our consolidated financial statements.

In June 2014, the FASB issued Accounting Standards Update 2014-12, Compensation-Stock Compensation (“ASU 2014-12”). The FASB issued ASU 2014-12 to provide specific guidance on share-based payment awards that provide for achievement of a specific performance target that could be achieved after the requisite service period. ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period should be treated as a performance condition. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. This guidance is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, which is effective for our fiscal year beginning July 1, 2016, the first day of our 2017 fiscal year. Earlier adoption is permitted. ASU 2014-12 may be applied prospectively to all awards granted or modified after the effective date or retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. If retrospective transition is adopted, the cumulative effect of applying this guidance should be recognized in the financial statements as an adjustment to the opening retained earnings balance at that date. We are currently evaluating the impact of this accounting guidance and do not expect any significant impact on our consolidated financial statements.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In August 2014, the FASB issued Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40) (“ASU 2014-15”). ASU 2014-15 provides guidance to U.S. GAAP about management’s responsibility to evaluate whether there is a substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This new rule requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles currently in U.S. auditing standards. Specifically, ASU 2014-15 (1) defines the term substantial doubt, (2) requires an evaluation of every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plan, (4) requires certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) requires an express statement and other disclosures when substantial doubt is not alleviated, and (6) requires an assessment for a period of one year after the date that the financial statements are issued. This guidance is effective for annual periods ending after December 15, 2016, which is effective for our fiscal year beginning July 1, 2016, the first day of our 2017 fiscal year. We are currently evaluating the impact of this accounting guidance and do not expect any significant impact on our consolidated financial statements.

In July 2015, the FASB issued Accounting Standards Update 2015-11, Inventory (Topic 330) (“ASU 2015-11”). ASU 2015-11 was issued to more closely align the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards. The core principle of this updated guidance is that an entity should measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in ASU 2015-11 apply to inventory that is measured using the first-in, first-out or average cost methods. ASU 2015-11 amends some of the guidance in Topic 330 to more clearly articulate the requirements for the measurement and disclosure of inventory, but the clarifications are not intended to result in any changes in practice other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost or net realizable value for inventory. There are no other substantive changes to the guidance on the measurement of inventory. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, which is effective for our fiscal year beginning July 1, 2017, the first day of our 2018 fiscal year. We are currently evaluating the impact of this accounting guidance and do not expect any significant impact on our consolidated financial statements.

In August 2015, the FASB issued Accounting Standards Update 2015-15, Interest – Imputation of Interest (Subtopic 835-30) Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (“ASU 2015-15”). ASU 2015-15 states that Staff at the Securities and Exchange Commission would not object to an entity deferring or presenting debt issuance costs as an asset and subsequently amortizing deferred debt issuance cost ratably over the term of the line-of-credit arrangement, regardless of whether there were outstanding borrowings under the arrangement. We are currently evaluating the impact of this accounting guidance and do not expect any significant impact on our consolidated financial statements.

Fair Value Measurement

Accounting Standards Codification (“ASC”) 820, “Fair Value Measurements and Disclosures,” establishes a three-level fair value hierarchy to classify the inputs used in measuring fair value, which are as follows:

Level 1 inputs to the valuation methodology are based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 inputs to the valuation methodology are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 inputs to the valuation methodology are based on unobservable inputs that reflect the company’s own assumptions about the assumptions market participants would use in pricing the asset or liability.

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Our financial instruments at December 31, 2015 and June 30, 2015 include cash equivalents, restricted cash, accounts receivable, accounts payable and borrowings under our senior secured convertible promissory note, senior secured promissory note and a revolving line of credit. The carrying amounts of cash and cash equivalents, restricted cash, receivables, and accounts payable are representative of their respective fair values because of the short-term maturities or expected settlement dates of these instruments. The fair value of debt, included in Note 13, is based on the fair value of similar instruments. These instruments are short-term in nature and there is no known trading market for our debt

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The following table provides the non-recurring fair value measurements of assets and liabilities as of December 31, 2015:


		Fair Value Measurements as of December 31, 2015
Description (In thousands)	Carrying Value at December 31, 2015	Quoted Prices in Active Markets for Identical Asset Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3
Certificates of deposit	$ 312	$ 312	$ -	$ -
Senior secured promissory note – BAM	20,000	-	-	20,000
Senior secured convertible promissory note – Montsant	3,184	-	-	3,184
Second senior secured convertible promissory note – DMRJ	12,000	-	-	12,000
Third senior secured convertible promissory note – DMRJ	12,000	-	-	12,000
Senior secured promissory note - DMRJ	1,000	-	-	1,000
Line of credit - DMRJ	16,862	-	-	16,862

The following table provides the non-recurring fair value measurements of assets and liabilities as of June 30, 2015:


		Fair Value Measurements as of June 30, 2015
Description (In thousands)	Carrying Value at June 30, 2015	Quoted Prices in Active Markets for Identical Asset Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3
Certificates of deposit	$ 312	$ 312	$ -	$ -
Senior secured promissory note – BAM	20,000	-	-	20,000
Senior secured convertible promissory note – Montsant	3,184	-	-	3,184
Senior secured promissory note - DMRJ	1,000	-	-	1,000
Second senior secured convertible promissory note – DMRJ	12,000	-	-	12,000
Third senior secured convertible promissory note – DMRJ	12,000	-	-	12,000
Line of credit - DMRJ	16,662	-	-	16,662

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

4. Restricted Cash and Investments

As of December 31, 2015 and June 30, 2015, we had restricted cash and investments, with maturities of less than one year, of $367,000. Restricted cash and investments consisted of the following:


(In thousands)	December 31, 2015	June 30, 2015
Current assets
Certificates of deposit	$ 312	$ 312
Cash maintained to secure corporate credit card	55	55
Total	$ 367	$ 367

The restricted investments of $312,000 held in certificates of deposit collateralize our performance under an irrevocable letter of credit issued in April 2010, aggregating to $297,000, in connection with our contract with the India Ministry of Defence, plus the bank required collateralization deposit of $15,000. The letter of credit provides warranty performance security equal to 5% of the contract amount under the terms of the contract with the India Ministry of Defence. We have amended the letter of credit, extending the expiration date to May 28, 2016.

In May 2015, we entered into a corporate credit card agreement with our primary bank, pursuant to which the bank reserves $55,000 of the available cash held in our operating account maintained with the bank to collateralize 105% of the credit limit that is available under the credit card agreement.

Stock Based Compensation

For the three months ended December 31, 2015 and 2014, our condensed consolidated statements of operations and comprehensive loss include $326,000 and $535,000, respectively, of compensation costs and no income tax benefit related to our stock-based compensation arrangements for employee and non-employee director awards. For the six months ended December 31, 2015 and 2014, our condensed consolidated statements of operations and comprehensive loss include $668,000 and $1,227,000, respectively, of compensation costs and no income tax benefit related to our stock-based compensation arrangements for employee and non-employee director awards, as follows:


	For the Three Months Ended December 31,		For the Six Months Ended December 31,
(In thousands)	2015	2014	2015	2014
Cost of revenues	$ 31	$ 53	$ 61	$ 101
Research and development	46	120	130	242
Selling, general and administrative	249	362	477	884
Total	$ 326	$ 535	$ 668	$ 1,227

As of December 31, 2015, the total amount of unrecognized stock-based compensation expense was approximately $1,741,000, which will be recognized over a weighted average period of 1.66 years.

As of December 31, 2015, there were options outstanding to purchase 21,076,651 shares of our common stock at exercise prices ranging from $0.08 to $2.30, with a weighted-average exercise price of $1.14.

Related Party Transactions

In April 2011, we entered into an advisory and consulting agreement with Robert Liscouski, our President and a member of our Board of Directors, to assist our U.S. government sales and marketing team with our efforts to advance our interests with the U.S. government. During the three and six months ended December 31, 2014, we paid Mr. Liscouski $60,000 and $105,000, respectively for services performed under this agreement which terminated effective on February 1, 2015, when Mr. Liscouski joined the Company. As of December 31, 2015, we had no obligation to Mr. Liscouski under this agreement.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

On August 15, 2014, August 29, 2014, September 18, 2014 and October 2, 2014, Roger Deschenes, our Chief Financial Officer, advanced $100,000, $125,000, $125,000 and $100,000, respectively, for general working capital purposes, of which $450,000 of principal and $12,000 of interest has been repaid to Mr. Deschenes during the fiscal year ended June 30, 2015. The advances were payable on demand and bore interest at 15%. As of December 31, 2015 our obligation to Mr. Deschenes was $0.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


(In thousands)	December 31, 2015	June 30, 2015
Inventory deposits	$ 280	$ 677
Insurance	58	87
Bank fees	6	14
Other prepaid expenses	147	168
Total	$ 491	$ 946

Inventories, net

We value our inventories at lower of cost or market. Cost is determined by the first-in, first-out (FIFO) method, including material, labor and factory overhead. The components of inventories, net of reserves, consist of the following:


(In thousands)	December 31, 2015	June 30, 2015
Raw materials	$ 3,895	$ 3,283
Work in progress	1,418	1,455
Finished goods	1,410	506
Total	$ 6,723	$ 5,244

As of December 31, 2015 and June 30, 2015, our reserves for excess and slow-moving inventories were $213,000 and $218,000, respectively.

Property and Equipment, net

Property and equipment consist of the following:


(In thousands)	December 31, 2015	June 30, 2015
Machinery and equipment	$ 553	$ 533
Computers and software	432	415
Furniture and fixtures	91	83
Leasehold improvements	173	159
Equipment under capital lease	159	157
Construction in progress	342	342
Sub-total	1,750	1,689
Less: accumulated depreciation and amortization	909	809
Total	$ 841	$ 880

For the three months ended December 31, 2015 and 2014, depreciation expense was approximately $50,000 and $40,000, respectively.

For the six months ended December 31, 2015 and 2014, depreciation expense was approximately $104,000 and $81,000, respectively.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

10. Accrued Expenses – Current and Long-Term

Accrued expenses consist of the following:


(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Accrued interest	$ 18,108	$ 13,264
Accrued compensation and benefits	3,299	1,774
Accrued warranty costs	1,337	556
Accrued legal and accounting	52	257
Accrued taxes	146	74
Other accrued liabilities	1,817	1,155
Total	$ 24,759	$ 17,080

Long-term liabilities
Accrued compensation and benefits	$ -	$ 48
	$ -	$ 48

On January 16, 2015, Glenn D. Bolduc, resigned his positions as Chief Executive Officer and President of the Company), as well as his seat on the Company’s Board of Directors and his position as Chairman of the Board. In connection with and prior to Mr. Bolduc’s resignations, Mr. Bolduc entered into a Separation Agreement and Release (the “Separation Agreement”) with the Company. The Separation Agreement provides that Mr. Bolduc’s resignation will be deemed an involuntary termination without cause pursuant to his Amended and Restated Employment Agreement dated as of June 25, 2013. In this regard, and subject to the terms contained in the Employment Agreement, Mr. Bolduc is entitled to receive: (i) annual base salary for 18 months on a regular payroll basis; (ii) a pro rata portion of any bonus earned in 2015; (iii) continuation of coverage under and contributions to health care, dental and life insurance benefits for a 12 month period; and (iv) transfer of any key man life insurance. In connection with Mr. Bolduc’s resignation, we recorded a non-recurring charge of $725,000 in our consolidated statements of operations and comprehensive loss for the year ended June 30, 2015. As of December 31, 2015 and June 30, 2015, $327,000 and $480,000, respectively, of separation benefits are included in accrued expenses in our condensed consolidated financial statements.

11.

Deferred Revenues – Current and Long-Term

Deferred revenues are recorded when we receive payments for product or services for which we have not yet completed our obligation to deliver product or have not completed services required by the contractual agreements.

As of December 31, 2015 and June 30, 2015, we had customer advance payment and extended warranty service agreements with maturities of less than one year, of $1,466,000 and $3,454,000, respectively, and extended warranty service agreements, with maturities of more than one year, of $355,000 and $221,000, respectively. Deferred revenues consisted of the following:


(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Customer advance payments	$ 1,033	$ 3,121
Extended warranty service agreements	433	333
Total	$ 1,466	$ 3,454
Long-term liabilities
Extended warranty service agreements	$ 355	$ 221
Total	$ 355	$ 221

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

12. Earnings Per Share

Basic earnings per share is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted earnings per share are based upon the weighted average number of common shares outstanding during the period plus additional weighted average common equivalent shares outstanding during the period. Common equivalent shares result from the assumed exercise of outstanding stock options and warrants, the proceeds of which are then assumed to have been used to repurchase outstanding common stock using the treasury stock method and assumed conversion of certain convertible promissory notes and convertible preferred stock. In addition, the numerator is adjusted for any changes in income or loss that would result from the assumed conversion of potential shares. As of December 31, 2015 and 2014, potentially dilutive shares are excluded from the earnings per share calculation, because their effect would be antidilutive. Shares deemed to be antidilutive include stock options, warrants, convertible debt and convertible preferred stock.


	For the Three Months Ended December 31,		For the Six Months Ended December 31,
(In thousands, except share and per share amounts)	2015	2014	2015	2014
Basic and diluted loss per share:
Numerator:
Net loss	$ (3,313)	$ (6,244)	$ (4,224)	$ (11,619)
Denominator:
Weighted average shares	78,528,620	70,938,120	77,367,787	67,842,872
Basic and diluted loss per share	$ (0.04)	$ (0.09)	$ (0.05)	$ (0.17)

Common stock equivalents excluded from the diluted earnings per share calculation for the three and six months ended December 31, 2015 and 2014, were as follows:


	For the Three Months Ended December 31,		For the Six Months Ended December 31,
	2015	2014	2015	2014
Common stock equivalents excluded
Stock options	556,561	2,141,637	686,859	2,406,659
Warrants	-	579,207	32,396	689,052
Convertible debt	39,800,000	60,978,666	39,800,000	60,978,666
	40,356,561	63,699,510	40,519,255	64,074,377

13.

Long-Term Debt and Credit Arrangements

Term Debt and Revolving Credit Facility with DMRJ Group, LLC and Term Debt with Montsant Partners, LLC

We are a party to several loan and credit agreements with DMRJ Group LLC (“DMRJ”), an accredited institutional investor. In December 2008, we entered into a note and warrant purchase agreement with DMRJ pursuant to which we issued a senior secured convertible promissory note in the principal amount of $5,600,000 and a warrant to purchase 1,000,000 shares of our common stock. Thereafter, we entered into a series of amendments, waivers and modifications of this facility. The note, which is collateralized by all of our assets, originally bore interest at 11.0% per annum.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

reserved for the purpose of issuance, 150% of the aggregate number of shares of our common stock issuable upon exercise of the warrant; that we maintain a minimum cash balance of at least $500,000; that the aggregate dollar amount of all accounts payable be no more than 100 days past due; and that we maintain a current ratio, defined as current assets divided by current liabilities, of no less than 0.60 to 1.00.

In September 2011, we amended each of our credit instruments with DMRJ. Pursuant to those amendments: (i) the maturity of our indebtedness to DMRJ was extended from September 30, 2011 to March 31, 2013; (ii) DMRJ waived our compliance with certain financial covenants in the notes and all related credit agreements through maturity; (iii) our line of credit under the September 2009 credit agreement was increased from $15,000,000 to $23,000,000; and (iv) we were required to repay sufficient amounts of our outstanding indebtedness under the notes and related credit agreements and other amounts owing to DMR such that as of December 31, 2011, the outstanding obligations to DMRJ shall not exceed $15,000,000.

In October 2011, we further amended each of our credit instruments with DMRJ, to eliminate the obligation to repay any portion of our outstanding indebtedness to DMRJ by December 31, 2011.

In February 2012, we amended each of our credit instruments with DMRJ, to extend the maturity of all of our indebtedness to DMRJ to September 30, 2012.

In September 2012, we further amended each of our credit instruments with DMRJ. Pursuant to those amendments: (i) we extended the maturity date of all of our indebtedness from September 30, 2012 to March 31, 2013 and (ii) issued to DMRJ a second senior secured convertible promissory note in the principal amount of $12,000,000 (the “September 2012 Note”).

The second senior secured convertible promissory note bears interest at the rate of 15% per annum. The principal balance of this note, together with all outstanding interest and all other amounts owed thereunder, was due and payable on March 31, 2013. The second senior secured convertible promissory note is convertible in whole or in part, at DMRJ’s option, into shares of Series H Convertible Preferred Stock at an initial conversion rate of $1,000 per share (as adjusted in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series H Preferred Stock, the “Series H Original Issue Price”).

The second senior secured convertible promissory note originally gave DMRJ the option to require us to repurchase any or all of the shares of Series H Preferred Stock owned by DMRJ, at the Series H Original Issue Price per share, if we did not (i) by March 31, 2013, have at least one of our products receive qualified or approved status on the “Transportation Security Administration Air Cargo Screening Technology List (ACSTL) – For Passenger Aircraft” or placed on the Transportation Security Administration’s “Explosive Trace Detector Qualified Product List (QPL)”; or (ii) achieve revenues of at least $7,500,000 per fiscal quarter, commencing with fiscal quarter ending June 30, 2013. As described below, the note was subsequently amended to eliminate this option.

The holders of the Series H Preferred Stock will be entitled to receive, prior to the payment of any dividends with respect to our Common Stock and/or Series G Convertible Preferred Stock, cumulative dividends on each share of Series H Preferred Stock at a rate equal to 15% of the Series H Original Issue Price per annum, (i) when, as and if declared by our Board of Directors, (ii) upon a liquidation, dissolution or winding up of the Company (a “Liquidation Event”), or (iii) upon the repurchase or conversion of the Series H Preferred Stock All dividends accruing on the Series H Preferred Stock are payable by the issuance of additional shares of Series H Preferred Stock.

Upon a Liquidation Event, the holders of shares of Series H Preferred Stock then outstanding will be entitled to be paid out of the assets of the company available for distribution to its stockholders, before any payment is made to the holders of Common Stock and/or Series G Preferred Stock in respect of such stock, an amount per share equal to the Series H Original Issue Price, plus any accrued but updated dividends thereon, whether or not declared. At the option of holders of a majority of the outstanding Series H Preferred Stock, (i) a consolidation or merger of us with or into another entity or person, or any other corporate reorganization, in which our stockholders immediately prior to such consolidation, merger or reorganization do not hold at least a majority of the resulting or surviving entities’ voting power immediately following such consolidation, merger or reorganization, or (ii) a sale or transfer of all or substantially all of our assets for cash, securities or other property, will be deemed to be a Liquidation Event.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Price” will initially be equal to $1,090, and is subject to adjustment in the event that (a) we issue additional shares of Common Stock as a dividend or other distribution on outstanding shares of Common Stock, (b) there is a split or subdivision of outstanding shares of Common Stock, or (c) there is a combination or reverse stock split of outstanding shares of Common Stock into a smaller number of shares of Common Stock. Assuming no adjustments to the Series H Original Issue Price or the Series H Conversion Price, the New Note will be convertible indirectly, at DMRJ’s option, into shares of Common Stock at an effective conversion price of $1.09 per share, which represents a discount of approximately 20% from the daily volume weighted average price of the Common Stock over the 20 trading days preceding the date of the amendment.

The holders of the Series H Preferred Stock will have no voting rights except as required by applicable law. However, without the consent of the holders of a majority of the outstanding Series H Preferred Stock, we may not (i) amend, alter or repeal any provision of its Articles of Organization or By-laws in a manner that adversely affects the powers, preferences or rights of the Series H Preferred Stock; (ii) authorize or issue any equity securities (or any equity or debt securities convertible into equity securities) ranking prior and superior to the Series H Preferred Stock with respect to dividends, distributions, redemption rights or rights upon liquidation, dissolution or winding up; or (iii) consummate any capital reorganization or reclassification of any of its equity securities (or debt securities convertible into equity securities) into equity securities ranking prior and superior to the Series H Preferred Stock with respect to dividends, distributions, redemption rights or rights upon liquidation, dissolution or winding up.

On February 28, 2013, we further amended each of our credit instruments with DMRJ. Pursuant to those amendments:

the maturity of all of our indebtedness to DMRJ was extended from March 31, 2013 to March 31, 2014;

DMRJ waived our compliance with certain financial covenants in each of our promissory notes and all related credit agreements through the new maturity date;

DMRJ’s option to require us to repurchase any or all of the shares of Series H Convertible Preferred Stock ) which may be issued upon conversion of the September 2012 Note was eliminated;

we issued to DMRJ a third senior secured convertible promissory note dated February 28, 2013, in the aggregate principal amount of $12,000,000. Payment for the February 2013 Note was made by the cancellation of $12,000,000 of principal of the outstanding indebtedness under our credit agreement;

DMRJ acquired the option to convert the amended and restated senior secured convertible promissory note dated March 12, 2012 (the “March 2012 Note”) into shares of Series J Convertible Preferred Stock in lieu of shares of Common Stock; and

the March 2012 Note and the September 2012 Note were amended to permit us to prepay any or all of our indebtedness thereunder on 30 days prior notice.

The third senior secured convertible promissory note bears interest at the rate of 15% per annum. The principal balance of this note, together with all outstanding interest and all other amounts owed thereunder, were due and payable on March 31, 2015. The third senior secured convertible promissory note is convertible in whole or in part, at DMRJ’s option, into shares of Series I Convertible Preferred Stock at an initial conversion rate of $1,000 per share (as adjusted in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series I Preferred Stock, the “Series I Original Issue Price”). We may prepay this note on 30 days prior notice.

As amended, the March 2012 Note is convertible in whole or in part, at DMRJ’s option, into shares of Series J Convertible Preferred Stock at an initial conversion rate of $1,000 per share (as adjusted in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series J Preferred Stock, the “Series J Original Issue Price”).

The holders of the Series I Preferred Stock will be entitled to receive, prior to the payment of any dividends with respect to our Common Stock and/or Series G Preferred Stock, cumulative dividends on each share of Series I Preferred Stock at a rate equal to 15% of the Series I Original Issue Price per annum, (i) when, as and if declared by our Board of Directors, (ii) upon a “Liquidation Event”, or (iii) upon the conversion of the Series I Preferred Stock All dividends accruing on the Series I Preferred Stock are payable by the issuance of additional shares of Series I Preferred Stock.

The holders of Series J Preferred Stock will be entitled to participate on an “as converted” basis in all dividends or distributions declared or paid on our Common Stock.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Upon a Liquidation Event, the holders of shares of Series I Preferred Stock and Series J Preferred Stock then outstanding will be entitled to be paid out of the assets of the company available for distribution to its stockholders, pari passu with distributions made with respect to the Series H Preferred Stock but before any payment is made to the holders of Common Stock and /or Series G Preferred Stock in respect of such stock, (i) an amount per share of Series I Preferred Stock equal to the Series I Original Issue Price, plus any accrued but updated dividends thereon, whether or not declared, and (ii) an amount per share of Series J Preferred Stock equal to the Series J Original Issue Price, plus any dividends declared but unpaid thereon. At the option of holders of a majority of the outstanding Series I Preferred Stock, (i) a consolidation or merger of the company with or into another entity or person, or any other corporate reorganization, in which the stockholders of the company immediately prior to such consolidation, merger or reorganization do not hold at least a majority of the resulting or surviving entities’ voting power immediately following such consolidation, merger or reorganization, or (ii) a sale or transfer of all or substantially all of our assets for cash, securities or other property, will be deemed to be a Liquidation Event.

Upon any such Liquidation Event, and after all payments described in the preceding paragraph are made in full in respect of the Series H Preferred Stock, the Series I Preferred Stock and the Series J Preferred Stock, the holders of the Series G Preferred Stock will be entitled to be paid out of the assets of the company available for distribution to its stockholders an amount equal to $8.00 per share of Series G Preferred Stock, plus any declared but unpaid dividends, prior to the payment of any amounts to the holders of our Common Stock by reason of their ownership of such stock.

Each share of Series I Preferred Stock will be convertible, at the option of the holder, into that number of shares of Common Stock as is determined by (i) dividing the Series I Original Issue Price by the Series I Conversion Price (as defined below) in effect at the time of conversion and (ii) multiplying the result by 1,000. The “Series I Conversion Price” will initially be equal to $1,180.00, and is subject to adjustment in the event that (a) we issue additional shares of Common Stock as a dividend or other distribution on outstanding shares of Common Stock, (b) there is a split or subdivision of outstanding shares of Common Stock, or (c) there is a combination or reverse stock split of outstanding shares of Common Stock into a smaller number of shares of Common Stock. Assuming no adjustments to the Series I Original Issue Price or the Series I Conversion Price, the February 2013 Note will be convertible indirectly, at DMRJ’s option, into shares of Common Stock at an effective conversion price of $1.18 per share, which represents premium of approximately 3% over the closing price of the Common Stock on the trading day preceding the date of the February 28, 2013 amendments.

Each share of Series J Preferred Stock will be convertible, at the option of the holder, into that number of shares of Common Stock as is determined by dividing the Series J Original Issue Price by the Series J Conversion Price (as defined below) in effect at the time of conversion. The “Series J Conversion Price” will initially be equal to $.08, and is subject to adjustment in the event that (a) the Company issues additional shares of Common Stock as a dividend or other distribution on outstanding shares of Common Stock, (b) there is a split or subdivision of outstanding shares of Common Stock, or (c) there is a combination or reverse stock split of outstanding shares of Common Stock into a smaller number of shares of Common Stock. Assuming no adjustments to the Series J Original Issue Price or the Series J Conversion Price, the March 2012 Note will be convertible indirectly, at DMRJ’s option, into shares of Common Stock at an effective conversion price of $.08 per share. Prior to the execution of the amendment, the March 2012 Note was convertible directly into shares of Common Stock at a conversion price of $.08 per share. Accordingly, we do not believe this change to be material.

The holders of the Series I Preferred Stock and the Series J Preferred Stock will have no voting rights except as required by applicable law. However, without the consent of the holders of a majority of the outstanding Series I Preferred Stock or Series J Preferred Stock, as the case may be, with each such series voting as a separate class, we may not (i) amend, alter or repeal any provision of our Articles of Organization or By-laws in a manner that adversely affects the powers, preferences or rights of the Series I Preferred Stock or Series J Preferred Stock, as the case may be; (ii) authorize or issue any equity securities (or any equity or debt securities convertible into equity securities) ranking prior and superior to the Series I Preferred Stock or Series J Preferred Stock, as the case may be, with respect to dividends, distributions, redemption rights or rights upon liquidation, dissolution or winding up; or (iii) consummate any capital reorganization or reclassification of any of its equity securities (or debt securities convertible into equity securities) into equity securities ranking prior and superior to the Series I Preferred Stock or Series J Preferred Stock, as the case may be, with respect to dividends, distributions, redemption rights or rights upon liquidation, dissolution or winding up.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2015, there were no shares of Series H Preferred Stock, Series I Preferred Stock or Series J Preferred Stock outstanding.

On November 14, 2013, we amended each of our credit agreements with DMRJ to extend the maturity date of all of our indebtedness to DMRJ from March 31, 2014 to September 30, 2014.

On March 19, 2014, we further amended each of our credit instruments with DMRJ. Pursuant to those amendments:

the maturity of all of our indebtedness to DMRJ was extended from September 30, 2014 to March 31, 2015;

DMRJ waived our compliance with certain financial covenants in each of our promissory notes and all related credit agreements through the new maturity date;

DMRJ consented to the execution and delivery of the note purchase agreement with BAM and agreed to waive all prepayment limitations and prepayment notice requirements set forth in any of the credit documents to which DMRJ and the company are parties with respect to the repayments and prepayments financed by the sale of the notes.

DMRJ agreed to subordinate its first position security interest in all of our assets to BAM.

On March 19, 2015, we further amended each of our credit instruments with DMRJ, pursuant to which the maturity of all our indebtedness to DMRJ was extended from March 31, 2015 to March 31, 2016 and DMRJ waived our compliance with certain financial covenants contained in each of our promissory notes and all related credit agreements through the new maturity date.

Further, upon the occurrence of an event of default under certain provisions of our agreements with DMRJ, we could be required to pay default rate interest equal to the lesser of 2.5% per month and the maximum applicable legal rate per annum on the outstanding principal balance outstanding.

The note purchase agreement with Montsant contains restrictions and financial covenants including: (i) restrictions against declaring or paying dividends or making any distributions; against creating, assuming or incurring any liens; against creating, assuming or incurring any indebtedness; against merging or consolidating with any other company, against the sale, assignment, transfer or lease of our assets, other than in the inventory ordinary course of business; against making investments in any company, extending credit or loans, or purchasing stock or other ownership interest of any company; and (ii) covenants that we maintain a minimum cash balance of at least $500,000; that the weighted average age of all accounts payable be no more than 100 days past due; and that we maintain a current ratio, defined as current assets divided by current liabilities, of no less than 0.60 to 1.00. Montsant waived our compliance with certain financial covenants in our promissory notes through the maturity date, consistent with the financial covenants which have been waived in each of our promissory notes and all related credit agreements with DMRJ.

Further, upon the occurrence of an event of default under certain provisions of our agreement with Montsant, we could be required to pay default rate interest equal to the lesser of 2.5% per month and the maximum applicable legal rate per annum on the outstanding principal balance outstanding.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Term Debt with BAM

On March 19, 2014, we entered into a note purchase agreement with a group of institutional investors and BAM Administrative Services LLC (“BAM”), an administrative agent for the investors, pursuant to which we issued senior secured promissory notes in the aggregate principal amount of $20,000,000. The notes bear interest at 15% per annum and mature on March 31, 2015. The proceeds from the sale of the notes were used to repay (i) $17,624,000 of our outstanding indebtedness to DMRJ under the amended and restated revolving promissory note dated September 29, 2011 (ii) $1,809,000 of interest outstanding under the amended and restated promissory note and (iii) $567,000 of interest outstanding under our senior secured convertible promissory note dated September 5, 2012.

On March 19, 2015, we extended our credit agreement with BAM pursuant to which, amongst other matters, the interest rate increased to 16% per annum, commencing on April 1, 2015 and we extended the maturity date of our indebtedness from March 31, 2015 to March 31, 2016.

The notes purchase agreement contains restrictions and financial covenants including: (i) restrictions against declaring or paying dividends or making any distributions; against creating, assuming or incurring any liens; against creating, assuming or incurring any indebtedness; against merging or consolidating with any other company, against the sale, assignment, transfer or lease of our assets, other than in the inventory ordinary course of business ; against making investments in any company, extending credit or loans, or purchasing stock or other ownership interest of any company; and (ii) covenants that we maintain a minimum cash balance of at least $500,000; that the weighted average age of all accounts payable be no more than 100 days past due; and that we maintain a current ratio, defined as current assets divided by current liabilities, of no less than 0.60 to 1.00. BAM waived our compliance with certain financial covenants in our promissory notes through the maturity date, consistent with the financial covenants which have been waived in each of our promissory notes and all related credit agreements with DMRJ.

Further, upon the occurrence of an event of default under certain provisions of our agreements with BAM, we could be required to pay default rate interest equal to the lesser of 2.5% per month and the maximum applicable legal rate per annum on the outstanding principal balance outstanding.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

14. Stockholders’ Deficit

Common Shares Authorized

On July 1, 2015, at an Annual Meeting of Stockholders, our stockholders approved an amendment to the Company’s Restated Articles of Organization to increase the number of authorized shares of common stock by 50,000,000 shares to 250,000,000 shares. We have intentionally delayed the filing of Articles of Amendment to our Restated Articles of Organization with the Commonwealth of Massachusetts to effect that increase. As a result of the stockholder approval, we are authorized to issue 250,000,000 shares of our common stock.

Common Stock Options and Stock Purchase Warrants

In connection with various financing agreements and services provided by consultants, we have issued warrants to purchase shares of our common stock. The fair value of warrants issued is determined using a binomial option pricing model.

Common Stock Options

In December 2004, we adopted the 2004 Stock Option Plan (the “2004 Plan”). The 2004 Plan provides for the grant of incentive stock options and non-qualified stock options to employees and affiliates. The exercise price of the options equa1 100% of the fair market value on the date of the grant or 110% of the fair market value for beneficial owners of more than 10% of our stock. Options expire between five and ten years from the date of the option grant and have various vesting periods. Options may be exercised by delivering to the company cash in an amount equal to such aggregate exercise price of the options exercised, or with the consent of the Committee, shares of our common stock having a fair market value equal to such aggregate exercise price, a personal recourse note issued to the company in a principal amount equal to such aggregate exercise price, other acceptable consideration including a cashless exercise/resale procedure, or any combination of the foregoing. A total of 500,000 shares were originally reserved for issuance under the 2004 Plan. In December 2005, our stockholders approved an increase in the 2004 Plan from 500,000 shares to 1,000,000 shares. In December 2007, our stockholders approved an increase in the 2004 Plan from 1,000,000 shares to 2,000,000 shares. In March 2012, our stockholders approved an increase in the 2004 Plan from 2,000,000 shares to 4,000,000. The 2004 Plan expired in May 2014, as such no further options grants may be issued under this plan. In September 2012, our Board of Directors adopted an amendment to our 2004 Stock Option increasing the total number of shares of our common stock issuable thereunder from 4,000,000 shares to 20,000,000 shares. On July 1, 2015, at the 2015 Annual Meeting of Stockholders, the September 2012 amendment was approved by our stockholders.

On July 2, 2014, our Board of Directors adopted the 2014 Stock Option Plan (the “2014 Plan”). The 2014 Plan provides for the grant of incentive stock options and non-qualified stock options to employees and affiliates. The exercise price of the options equa1 100% of the fair market value on the date of the grant or 110% of the fair market value for beneficial owners of more than 10% of our stock. Options expire between five and ten years from the date of the option grant and have various vesting periods. Options may be exercised by delivering to the company cash in an amount equal to such aggregate exercise price of the options exercised, or with the consent of the Committee, shares of our common stock having a fair market value equal to such aggregate exercise price, a personal recourse note issued to the company in a principal amount equal to such aggregate exercise price, other acceptable consideration including a cashless exercise/resale procedure, or any combination of the foregoing. A total of 15,000,000 shares were originally reserved for issuance under the 2014 Plan. The 2014 Plan was approved by our stockholders on July 1, 2015 at the 2015 Annual Meeting of Stockholders.

As of December 31, 2015, there were options outstanding to purchase 21,076,651 shares of our common stock at exercise prices ranging from $0.08 to $2.30.

We issued 20,000 and 255,000 shares of common stock during the three months ended December 31, 2015 and 2014, respectively, as a result of the exercise of options by employees and consultants. We issued 83,000 and 488,999 shares of common stock during the six months ended December 31, 2015 and 2014, respectively, as a result of the exercise of options by employees and consultants.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Stock Purchase Warrants and Stock Issuances

In June 2015, we issued 550,000 shares of common stock having a value of $412,000 to two advisors, in consideration of services rendered to us under two advisory and consulting services agreements. The issued shares were valued at the closing stock price of $0.75 per share at May 6, 2015. The advisory and services agreements provide for the issuance of an additional 1,650,000 shares in equal monthly installments of 110,000 shares commencing in September 2015. For the six month ended December 31, 2015, we have issued 440,000 shares of common stock having a value of $331,000 to these two advisors for services rendered under the advisory and consulting services agreement.

As of December 31, 2015, there were warrants outstanding to purchase 3,155,000, shares of our common stock at exercise prices ranging from $0.54 to $1.22 expiring at various dates between May 25, 2016 and April 1, 2021.

15.

Income Taxes

We are required to file federal and state income tax returns in the United States. The preparation of these tax returns requires us to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by us. In consultation with our tax advisors, we base our tax returns on interpretations that are believed to be reasonable under the circumstances. The tax returns, however, are subject to routine reviews by the various federal and state taxing authorities in the jurisdictions in which we file tax returns. As part of these reviews, a taxing authority may disagree with respect to the income tax positions taken by us (“uncertain tax positions”) and, therefore, may require us to pay additional taxes. As required under applicable accounting rules, we accrue an amount for our estimate of additional income tax liability, including interest and penalties, which we could incur as a result of the ultimate or effective resolution of the uncertain tax positions. We account for income taxes using the asset and liability method. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributed to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences and carry-forwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.

We account for uncertain income tax positions by accruing for the estimated additional amount of taxes for the uncertain tax positions when the uncertain tax position does not meet the more likely than not standard for sustaining the position. We review and update our accrual as more definitive information becomes available from taxing authorities, upon completion of tax audits, upon expiration of statutes of limitation, or upon occurrence of other events. This requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. Significant judgment is required in assessing the timing and amounts of deductible and taxable items and the probability of sustaining uncertain tax positions. The benefits of uncertain tax positions are recorded in our consolidated financial statements only after determining a more-likely-than-not probability that the uncertain tax positions will withstand challenge, if any, from tax authorities. When facts and circumstances change, we reassess these probabilities and record any changes in the consolidated financial statements as appropriate.

Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and the tax basis of the assets and liabilities using the enacted tax rate in effect in the years in which the differences are expected to reverse. A valuation allowance has been recorded against the deferred tax asset as it is more likely than not, based upon our analysis of all available evidence, that the tax benefit of the deferred tax asset will not be realized.

A valuation allowance has been established for our tax assets as their use is dependent on the generation of sufficient future taxable income, which cannot be predicted at this time. Included in the valuation allowance is approximately $800,000 related to certain operating loss carryforwards resulting from the exercise of employee stock options, the tax benefit of which, when recognized, will be accounted for as a credit to additional paid-in capital rather than a reduction in income tax.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2015, the Company has the following unused net operating loss and tax credit carryforwards available to offset future federal and state taxable income, both of which expire at various times as noted below:


(In thousands)	Net Operating Losses	Investment AMT & Research Credits	Expiration Dates
Federal	$ 107,818	$ 1,455	2022 to 2035
State	$ 74,879	$ 983	2016 to 2035

We have recorded a full valuation allowance against our net deferred tax assets of $49,795,000 as of December 31, 2015, due to uncertainties related to our ability to utilize these assets. The valuation allowance is based on our estimates of taxable income and the period over which our deferred tax assets will be recoverable.

Potential 382 Limitation

Our net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service. Our ability to utilize our net operating loss (“NOL”) and alternative minimum tax (“AMT”) and research and development credit (“R&D”) carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state provisions. These ownership changes may limit the amount of NOL, AMT and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined in Section 382 of the Code, results from a transaction or series of transactions over a six-year period resulting in an ownership change of more than 50% of the outstanding stock of a company by certain stockholders or public groups.

We have not completed a study to assess whether one or more ownership changes have occurred since we became a loss corporation as defined in Section 382 of the Code, but we believe that it is likely that an ownership change has occurred. If we have experienced an ownership change, utilization of the NOL, AMT and R&D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of our common stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL, AMT or R&D credit carryforwards before utilization. Until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit under ASC 740. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding adjustment to the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any potential limitation will have a material impact on our operating results.

From time to time we may be assessed interest or penalties by major tax jurisdictions, namely the states of Massachusetts and California. As of December 31, 2015, we had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. No interest and penalties have been recognized by the Company to date.

Tax years 2012 through 2015 are subject to examination by the federal and state taxing authorities. There are no income tax examinations currently in process.

Our net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and are subject to certain limitations in the event of cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%.

16.

Commitments and Contingencies

On April 1, 2013, we entered into a lease for manufacturing, research and office space in Wilmington, Massachusetts, the lease of which expires on June 30, 2020. Under the terms of the lease, we are responsible for our proportionate share of real estate taxes and operating expenses relating to this facility. We leased research and office space in San Diego, California and leased 300 square feet of office space in Shanghai, China. On March 25, 2015, our Board of Directors approved restructuring actions to better align costs with current and future geographic revenue sources and to improve efficiencies. In November, 2015, we exited from our lease in San Diego, CA. Total rent expense, including assessments for maintenance and real estate taxes for the six months ended December 31, 2015 and 2014, was $363,000 and $437,000, respectively.

IMPLANT SCIENCES CORPORATION

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

License Agreements

We are obligated under one license agreement, assumed in connection with the acquisition of Ion Metrics, whereby we were granted rights to use certain intellectual property for safety, security and narcotic applications, which we intend to incorporate into future security product offerings for certain minimum guaranteed annual payments. The license agreement expires on September 30, 2016 and as of December 31, 2015, we have no obligation under this license agreement for future minimum guaranteed payments.

17.

Financial Information By Segment

Operating segments are defined as components of an enterprise about which separate financial information is available that is regularly evaluated by the chief operating decision maker or decision making group, in determining how to allocate resources and in accessing performance. Our chief operating decision making group is composed of the chief executive officer and members of senior management. Based on qualitative and quantitative criteria, we have determined that we operate within one reportable segment, which is the Security Products Segment.

18.

Legal

On March 23, 2015, Bernard Miller (“Mr. Miller”), individually and on behalf of all others similarly situated shareholders of the company, filed a complaint against Dr. William J. McGann, Messrs. Glenn D. Bolduc, John H. Hassett, John A. Keating, Robert P. Liscouski, Howard Safir and Michael C. Turmelle and the Company in the Suffolk Superior Court of the Commonwealth of Massachusetts, seeking derivative action as a result of director breaches of fiduciary duty and unjust enrichment. Amongst other things, the plaintiff requested that the court compel the Company to hold an annual stockholders’ meeting; subject the September 2012 Amendment to the 2004 Plan to a vote at the next annual stockholders’ meeting; rescind the stock option awards granted under the September 2012 Amendment to 2004 Plan in the event that the amendment is not approved by a majority of our stockholders’; impose a trust, in favor of the Company, for any benefits improperly received; and award costs and expenses, including reasonable attorney fees.

On July 1, 2015 we held our 2015 Annual Meeting of Stockholders. Stockholders approved an amendment to the Company’s 2004 Stock Option Plan to increase the aggregate number of shares of the Company’s common stock, par value $0.001 per share available for issuance under the Plan by 16,000,000 shares to 20,000,000 shares and approve the Company’s Amended and Restated 2014 Stock Option Plan.

On May 22, 2015, a motion to dismiss the Complaint with prejudice was served on the plaintiff and subsequently filed with the Court. On July 21, 2015, the Court endorsed an Order of Stipulation the parties entered into. The Stipulation provides, among other things, that the Complaint is dismissed with prejudice and the Motion to Dismiss is moot. On December 17, 2015, the Court ruled that the Plaintiff’s counsel was entitled to a fee of $70,000 together with costs of approximately $6,000. During the three and six months ended December 31, 2015, we recorded a charge of $76,000 in our condensed consolidated statement of operations and comprehensive loss which is included in current liabilities on our condensed consolidated balance sheets at December 31, 2015.

We are not currently a party to any other legal proceedings, other than routine litigation incidental to our business that which we believe will not have a material effect on our business, assets or results of operations. From time to time, we are subject to various claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of our business activities. Each of these matters may be subject to various uncertainties.

19.

Subsequent Events

We have evaluated subsequent events after the balance sheet date through the date these financial statements were issued for appropriate accounting and disclosure and concluded that there are no subsequent events requiring adjustment or disclosure in these financial statements.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s discussion and analysis of results of operations and financial condition (“MD&A”) is a supplement to the accompanying condensed consolidated financial statements and provides additional information on Implant Sciences Corporation’s (“Implant Sciences” or the “Company’) business, current developments, financial condition, cash flows and results of operations.

When we say “we,” “us,” “our,” “Company,” or “Implant Sciences,” we mean Implant Sciences Corporation and its subsidiaries.

Please see our Annual Report on Form 10-K for the fiscal year ended June 30, 2015 for a complete description of our business.

Overview

We develop, manufacture and sell sophisticated sensors and systems for the security, safety and defense industries. A variety of technologies are currently used worldwide in security and inspection applications. In broad terms, the technologies focus on detection in two major categories: (i) the detection of “bulk” contraband, which includes materials that would be visible to the eye, such as weapons, explosives, narcotics and chemical agents; and (ii) the detection of “trace” amounts of contraband, which includes trace particles or vapors of explosives, narcotics and chemical agents. Technologies used in the detection of “bulk” materials include computed tomography, transmission and backscatter x-ray, metal detection, trace detection and x-ray, gamma-ray, passive millimeter wave, and neutron analysis. Trace detection techniques used include mass spectrometry, gas chromatography, chemical luminescence, and ion mobility spectrometry.

We have developed proprietary technologies used in explosives and narcotics trace detection (“ETD” and “NTD”, respectively) applications and market and sell handheld ETD and desktop ETD and NTD systems that use our proprietary technologies. Our products are marketed and sold to a growing number of locations domestically and internationally. These systems are used by private companies and government agencies to screen baggage, cargo, other objects and people for the detection of trace amounts of explosives and narcotics.

A significant component of our ability to compete in the markets that we serve are the attainment of regulatory approvals. We have undertaken considerable efforts in the past twelve to eighteen months in this regard and have achieved the following regulatory approvals and customer orders:

Our QS-B220 desktop ETD system successfully completed and passed testing requirements for the TSA’s qualification test for aviation checkpoint and checked baggage and has been placed on the TSA’s Qualified Product List (“QPL”) on August 28, 2014. The QS-B220 is the first ETD with a non-radioactive source to be approved by the TSA for use in U.S. airports for passenger and baggage screening. We are now able to participate in TSA tenders for ETD procurements for aviation checkpoint and checked baggage screening.

On October 6, 2014, the QS-B220 successfully passed the European Civil Aviation Conference's (“ECAC”) Common Evaluation Process of Security Equipment (“CEP”) for airport checkpoint screening of passengers and baggage. The CEP was established to provide standards for security equipment performance across ECAC's 44 member nations.

On October 16, 2014, the U.S. Department of Homeland Security (“DHS”) selected our proposal to develop next generation explosives trace detection screening systems for funding. The project, pending successful negotiations, is potentially worth up to approximately $2 million. Subject to successful conclusion of negotiations with the DHS, we expect the project to commence in the fourth quarter of fiscal 2016.

On November 10, 2014, we entered into an Indefinite Delivery / Indefinite Quantity (“IDIQ”) contract with the United States Transportation Security Administration (“TSA”) for our QS-B220 desktop explosives trace detectors. The IDIQ, a necessary prerequisite for competing for TSA’s annual trace detection procurements and establishes contract terms under which the TSA could purchase up to $162 million of equipment and services.

On November 10, 2014, we received an initial delivery order from the TSA for 1,170 QS-B220 desktop explosives trace detectors and commenced shipments under the delivery order in December 2015.

On December 3, 2015, we announced that our Board of Directors has authorized management to retain financial advisors to explore strategic alternatives to maximize shareholder value.

Critical Accounting Policies

Our significant accounting policies are summarized in Note 2 to our consolidated financial statements included in Item 7 of our Annual Report on Form 10-K, for the fiscal year ended June 30, 2015. However, certain of our accounting policies require the application of significant judgment by our management, and such judgments are reflected in the amounts reported in our condensed consolidated financial statements. In applying these policies, our management uses judgment to determine the appropriate assumptions to be used in the determination of estimates. Those estimates are based on our historical experience, terms of existing contracts, our observance of market trends, information provided by our strategic partners and information available from other outside sources, as appropriate. Actual results may differ significantly from the estimates contained in our condensed consolidated financial statements.

Results of Operations

Three Months Ended December 31, 2015 vs. December 31, 2014

Revenues


	For the Three Months Ended December 31, 2015		For the Three Months Ended December 31, 2014
(In thousands)	Amount	Mix	Amount	Mix	Change
QS-B220	$ 7,557	73.4%	$ 1,163	54.3%	549.8%
QS-H150	1,725	16.8%	805	37.6%	114.3%
Parts and supplies	1,010	9.8%	173	8.1%	483.8%
Total	$ 10,292	100.0%	$ 2,141	100.0%	380.7%

Revenues for the three months ended December 31, 2015 were $10,292,000 as compared with $2,141,000 for the comparable prior year period, an increase of $8,151,000, or 380.7%. The increase in revenue is due primarily to a 818.0% increase in the number of QS-B220 desktop units sold in the three months ended December 31, 2015, due to the initial shipments under our delivery order with the U.S. Transportation Security Administration, increased shipments to European airports and increased shipments to Asia, Africa and South America in the current three month period, offset partially by a 29.2% decrease in the average unit sales prices, which resulted in a 549.8% increase in QS-B220 revenues. Factors impacting our average unit sales prices are mainly due to the competitive market conditions and our decision to offer early payment discounts to certain distributors to hasten collection of our accounts receivable, which discounts in the aggregate amounted to $97,000 in the three months ended December 31, 2015.

QS-H150 handheld units sold in the three months ended December 31, 2015, increased 121.4%, compared to the prior period, due to increased shipments to Asia and Africa, which is partially offset by a 3.2% decrease in the average unit sales prices, which resulted in a 114.3% increase in QS-H150 revenues.

Sales of parts and supplies increased 483.8% in the three months ended December 31, 2015, due primarily to increased sales of consumables and other supplies that shipped with the QS-B220 desktop units in the current three month period.

Sales of QS-B220 were favorably impacted in the comparable prior period due to the acceptance of the QS-B220 into the “Qualified” section of the TSA’s Air Cargo Screening Technology List and achieving European Civil Aviation Conference (“ECAC”) Common Evaluation Process of Security Equipment for airport checkpoint screening of passengers and baggage. Competitive market conditions are expected to continue to have a negative impact on our average unit sales prices for the foreseeable future.

Cost of Revenues

Cost of revenues for the three months ended December 31, 2015 were $6,439,000 as compared with $1,777,000 for the comparable prior year period, an increase of $4,662,000 or 262.4%. The increase in cost of revenues recorded in the three months ended December 31, 2015 is primarily due to increased unit sales of our QS-B220 desktop units and increased unit sales of our QS-H150 handheld units.

Gross Margin

Gross margin for the three months ended December 31, 2015 was $3,853,000 or 37.4% of revenues as compared with $364,000 or 17.0% of revenues for the comparable prior year period. The increase in gross margin as a percent of revenues is primarily due to increased manufacturing overhead absorption, due to increased QS-B220 unit volume and lower material costs for the QS-B220 due to volume purchasing price reductions, partially offset by a decrease in the average unit sales price on sales of our QS-B220 units of 29.2%. and 3.2% decrease in the average unit sales price on sales of our QS-H150 units.

Research and Development Expense

Research and development expense for the three months ended December 31, 2015 was $901,000 as compared with $1,288,000 for the comparable prior year period, a decrease of $387,000 or 30.0%. The decrease in research and development expense is due primarily to the relocation of the San Diego, CA advanced technology office, which resulted in a $138,000 decrease in payroll and benefit costs, a $73,000 decrease in stock-based compensation, a $91,000 decrease in materials and prototype expense, a $32,000 decrease in rent expense, and a $16,000 decrease in engineering consulting expense. We continue to expend funds to further the development of new products in the areas of explosives and narcotics detection, and to obtain the necessary approvals from the TSA and other non-U.S. government approvals. Spending on research and development will increase in the next six to twelve months due to the ongoing development of the QS-B220 desktop detector, the development of the QS-H150E portable explosives and narcotics detector and continued development of a hyphenated system employing conventional ion mobility, differential mobility and quadrupole mass spectrometry.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended December 31, 2015 were $3,718,000 as compared with $3,195,000 for the comparable prior year period, an increase of $523,000, or 16.4%. The increase in selling, general and administrative expenses is due primarily a $594,000 increase in consulting expenses due to the issuance of shares of our common stock to two advisors for services rendered under the advisory and consulting services agreements, a $528,000 increase in payroll and related benefits due primarily to the provision of $480,000 for incentive compensation, a $298,000 increase in variable selling expenses, due to increased revenues and the $76,000 charge recorded for the plaintiff’s counsel fee and expenses, resulting from the Miller litigation, partially offset by a separation benefits of $725,000 provided to our former CEO due to his resignation in the prior year period, a $112,000 decrease in stock-based compensation on employee stock options, a $52,000 decrease in bad debt expense, and a $33,000 decrease in rent expense.

Other Expense

For the three months ended December 31, 2015, other expense was $2,547,000 as compared with other expense of $2,125,00, for the comparable prior year period, an increase of $422,000. The increase is due to increased interest expense on higher borrowings under our credit facilities with DMRJ and, to a lesser extent, the 1% increase in the BAM interest rate which took effect on April 1, 2015.

Net Loss

Our net loss for the three months ended December 31, 2015 was $3,313,000 as compared with a net loss of $6,244,000 for the comparable prior year period, a decrease of $2,931,000, or 46.9%. The decrease in the net loss is primarily due to increased revenues and gross margin, partially offset by increased operating expenses and an increase in interest expense.

Six Months Ended December 31, 2015 vs. December 31, 2014

Revenues


	For the Six Months Ended December 31, 2015		For the Six Months Ended December 31, 2014
(In thousands)	Amount	Mix	Amount	Mix	Change
QS-B220	$ 20,048	81.2%	$ 1,917	47.8%	945.8%
QS-H150	2,412	9.8%	1,791	44.7%	34.7%
Parts and supplies	2,225	9.0%	302	7.5%	636.8%
Total	$ 24,685	100.0%	$ 4,010	100.0%	515.6%

Revenues for the six months ended December 31, 2015 were $24,685,000 as compared with $4,010,000 for the comparable prior year period, an increase of $20,675,000, or 515.6%. The increase in revenue is due primarily to a 1,372.6% increase in the number of QS-B220 desktop units sold in the six months ended December 31, 2015, due to increased shipments to European airports, initial shipments under our delivery order with the U.S. Transportation Security Administration, and increased shipments to Asia, Africa and South America in the current six month period, offset partially by a 29.0% decrease in the average unit sales prices, which resulted in a 945.8% increase in QS-B220 revenues. Factors impacting our average unit sales prices are mainly due to the competitive market conditions and our decision to offer early payment discounts to certain distributors to hasten collection of our accounts receivable, which discountsin the aggr amounted to $307,000 in the six months ended December 31, 2015.

QS-H150 handheld units sold in the six months ended December 31, 2015, increased 38.5 %, compared to the prior period, due to increased shipments to Asia and Africa, which is partially offset by a 2.7% decrease in the average unit sales prices, which resulted in a 34.7% increase in QS-H150 revenues.

Sales of parts and supplies increased 636.8% in the six months ended December 31, 2015, due primarily to increased sales of consumables and other supplies that shipped with the QS-B220 desktop units in the current six month period.

Cost of Revenues

Cost of revenues for the six months ended December 31, 2015 were $14,575,000 as compared with $3,028,000 for the comparable prior year period, an increase of $11,547,000 or 381.3%. The increase in cost of revenues recorded in the six months ended December 31, 2015 is primarily due to increased unit sales of our QS-B220 desktop units and, to a lesser extent, increased unit sales of our QS-H150 handheld units.

Gross Margin

Gross margin for the six months ended December 31, 2015 was $10,110,000 or 41.0% of revenues as compared with $982,000 or 24.5% of revenues for the comparable prior year period. The increase in gross margin as a percent of revenues is primarily due to increased manufacturing overhead absorption, due to increased QS-B220 unit volume and lower material costs for the QS-B220 due to volume purchasing price reductions, partially offset by a 29.0% decrease in the average unit sales price on sales of our QS-B220 units and by a decrease in the average unit sales price on sales of our QS-H150 units of 2.7%.

Research and Development Expense

Research and development expense for the six months ended December 31, 2015 was $1,984,000 as compared with $2,572,000 for the comparable prior year period, a decrease of $588,000 or 22.9%. The decrease in research and development expense is due primarily to the relocation of the San Diego, CA advanced technology office, which resulted in a $251,000 decrease in payroll and benefit costs, a $139,000 decrease in materials and prototype expenses, a $112,000 decrease in stock-based compensation, a $62,000 decrease in regulatory testing expenses, and a $15,000 decrease in rent expense, offset partially by a $43,000 increase in travel expenses incurred in support of the ECAC system deployments in the current period. We continue to expend funds to further the development of new products in the areas of explosives and narcotics detection, and to obtain the necessary

approvals from the TSA and other non-U.S. government approvals. Spending on research and development will increase in the next six to twelve months due to the ongoing development of the QS-B220 desktop detector, the development of the QS-H150E portable explosives and narcotics detector and continued development of a hyphenated system employing conventional ion mobility, differential mobility and quadrupole mass spectrometry.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the six months ended December 31, 2015 were $7,256,000 as compared with $5,870,000 for the comparable prior year period, an increase of $1,386,000, or 23.6%. The increase in selling, general and administrative expenses is due primarily to a $1,291,000 increase in payroll and benefit costs, due to the provision of $960,000 for incentive compensation and a $200,000 sign on bonus for Mr. Liscouski, our President, a $858,000 increase in variable selling expenses due to increased revenues, a $588,000 increase in consulting expenses due to the issuance of shares of our common stock to two advisors for services rendered under the advisory and consulting services agreements, a $79,000 increase in travel expense incurred to support QS-B220 system installations in European, the $76,000 charge recorded for the plaintiff’s counsel fee and expenses, resulting from the Miller litigation $68,000 increase in legal fees, offset partially by separation benefits of $725,000 provided to our former CEO due to his resignation in the prior year period, a $406,000 decrease in stock-based compensation on employee stock options, a $198,000 decrease in stock-based compensation expense on non-employee warrants, a $53,000 decrease in bad debt expense, and a $46,000 decrease in rent expense.

Other Expense

For the six months ended December 31, 2015, other expense was $5,094,000 as compared with other expense of $4,159,000, for the comparable prior year period, an increase of $935,000. The increase is due to increased interest expense on higher borrowings under our credit facilities with DMRJ and, to a lesser extent, the 1% increase in the BAM interest rate which took effect on April 1, 2015.

Net Loss

Our net loss for the six months ended December 31, 2015 was $4,224,000 as compared with a net loss of $11,619,000 for the comparable prior year period, a decrease of $7,395,000, or 63.6%. The decrease in the net loss is primarily due to increased revenues and gross margin, partially offset by increased operating expenses and an increase in interest expense.

Liquidity and Capital Resources

As of December 31, 2015 and June 30, 2015, we had cash and cash equivalents of $776,000 and $1,985,000, respectively.

We will be required to repay all of our borrowings from DMRJ, Montsant and from a group of institutional investors for which BAM Administrative Services LLC (“BAM”) acts as administrative agent, on March 31, 2016. Our obligations to BAM are secured by a security interest in substantially all of our assets. DMRJ and Montsant agreed to subordinate their security interest in all of our assets to the security interest held by BAM (See Note 13).

Our obligations to DMRJ are secured by security interests in substantially all of our assets. As of December 31, 2015, our obligations to DMRJ under each of the three promissory notes and a revolving line of credit approximated $12,000,000, $12,000,000, $1,000,000 and $16,862,000, respectively. Further, as of December 31, 2015, our obligation to DMRJ for accrued interest under these instruments approximated $14,559,000 and is included in accrued expenses in the condensed consolidated financial statements.

Our obligations to the investors are secured by security interests in substantially all of our assets. As of December 31, 2015, our obligations under the senior secured promissory notes for which BAM is the agent were $20,000,000. Further, as of December 31, 2015, our obligation under such notes for accrued interest amounted to approximately $1,690,000 and is included in accrued expenses in the condensed consolidated financial statements.

Each of these notes and the credit facility are described in Note 13 of the Notes to Condensed Consolidated Financial Statements, accompanying this Quarterly Report.

Pursuant to the terms of the Purchase Agreement, we will receive from RCA, within two business days of the submission of the applicable invoice, an initial payment equal to 90% of the face value of an Eligible Receivable purchased by RCA. Following payment of such Eligible Receivable to RCA by the relevant customer, RCA shall pay the Company the residual 10% of such receivable, less fees payable to RCA by the Company pursuant to the Purchase Agreement.

We have paid, or will pay, as applicable, the following fees, as applicable, to RCA pursuant to the Purchase Agreement: (i) an initial enrollment fee equal to $5,000.00; (ii) a discount factor equal to 0.35%, for U.S. government contracts (or 0.53% for U.S. government subcontracts), of the amounts of purchased receivables; (iii) a program access fee equal to 0.017% of the daily ending account balance for each day that receivables are outstanding; (iv) a commitment fee equal to 1% of Maximum Amount minus the amount of purchased receivables; and (v) expenses relating to the negotiation of the Purchase Agreement, which amount is not expected to exceed $1,000. As of December 31, 2015, we had not yet sold any receivables to RCA pursuant to the Purchase Agreement.

BAM Administrative Services LLC and DMRJ Group LLC consented to the transactions contemplated by the Purchase Agreement.

During the six months ended December 31, 2015, we had net cash outflows of $1,373,000 from operating activities as compared to net cash outflows from operating activities of $5,895,000 for the comparable prior year period. The $4,522,000 decrease in net cash outflows used in operating activities during the six months ended December 31, 2015, as compared to the prior year period, was due to the following changes in working capital: (i) a $5,237,000 increase in accounts receivable, compared to a $416,000 increase in the prior period, due to increased product shipments during the latter part of the quarter ended December 31, 2015; (ii) a $1,479,000 increase in inventories compared to a $170,000 decrease in the prior period, due primarily to increased customer order backlog, compared to the prior period; (iii) an increase in accrued expenses of $7,885,000, compared to a $3,125,000 increase in the prior period, due to primarily to an increase in our accrued interest, due to higher borrowings under our credit facilities with DMRJ and the increase in the BAM interest rate, and to a lesser extent, by an increase in accrued expenses in the current period due provisions for incentive compensation recorded in the six months ended December 31, 2015 and an increase in our provision for product warranty costs, due to increased unit shipments of our QS-B220 desktop units; (iv) a $1,854,000 decrease in deferred revenue, compared to a $1,279,000 increase in deferred revenue in the prior year period, due primarily to the application of ECAC customer advance deposits received in the quarter ended June 30, 2015, against accounts receivables resulting from shipments in the six months ended December 31, 2015; and, (v) a $1,942,000 increase in accounts payable, compared to a $134,000 decrease in the prior period, due to increased inventory related payables.

During the six months ended December 31, 2015, we had net cash outflows of $65,000 from investing activities as compared to net cash outflows of $314,000 from investing activities for the prior year period. The $249,000 decrease in net cash used in investing activities during the six months ended December 31, 2015, as compared to the prior year period, was primarily due to increased purchases of equipment in the six months ended December 31, 2014.

During the six months ended December 31, 2015 we had net cash inflows of $210,000 from financing activities as compared to net cash inflows of $5,843,000 for the comparable prior year period. The $5,633,000 decrease in net cash from financing activities during the six months ended December 31, 2015, as compared to the prior year period, was primarily due to $200,000 in borrowings under our credit facility with DMRJ, compared to a borrowings of $5,605,000 in the prior fiscal year, and, to a lesser extent, a $227,000 decrease in proceeds received due to the exercise of stock options and warrants.

Credit Facilities with DMRJ Group LLC, Montsant Partners LLC and BAM Administrative Services LLC

In December 2008, we entered into a note and warrant purchase agreement with DMRJ, pursuant to which we issued a senior secured convertible promissory note in the principal amount of $5,600,000 and a warrant to purchase 1,000,000 shares of our common stock. Thereafter, we entered into a series of amendments, waivers and modifications of this facility. The notes mature on March 31, 2016.

On May 4, 2015, we entered into an assignment agreement with DMRJ and Montsant, wherein DMRJ assigned its rights, title and interest in the senior secured promissory note dated December 10, 2008 and appointed DMRJ as its collateral agent under the promissory note agreement. The note matures on March 31, 2016. DMRJ and Montsant are funds managed by Platinum Partners Value Arbitrage Fund LP.

In March, 2014, we entered into a note purchase agreement with a group of institutional investors and BAM, an administrative agent for the investors, pursuant to which we issued senior secured promissory notes in the aggregate principal amount of $20,000,000. The notes bear interest at 16% per annum and mature on March 31, 2016. We used all of the proceeds from the sale of the notes to repay (i) $17,624,000 of our outstanding indebtedness to DMRJ under revolving promissory note (ii) $1,809,000 of interest outstanding under that facility and (iii) $567,000 of interest outstanding under our senior secured convertible promissory note.

See Note 13 of Notes to Condensed Consolidated Financial Statements, accompanying this Quarterly Report. There can be no assurance that we will be successful in refinancing or extending our obligations to our secured lenders.

Despite our current sales, expense and cash flow projections and $3,084,000 in cash available from our line of credit with DMRJ, at February 5, 2016, to fund our operations and continue the development, commercialization and marketing of our products will require that we extend our credit facilities with DMRJ, BAM and Montsant. There can be no assurance that DMRJ will continue to make advances under our revolving line of credit. Our failure to achieve our projections and/or obtain sufficient additional capital on acceptable terms would have a material adverse effect on our liquidity and operations and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern.

Off-Balance Sheet Arrangements

As of December 31, 2015, we had one irrevocable standby letter of credit outstanding in the approximate amount of $297,000. The letter of credit provides warranty performance security equal to 5% of the contract amount with the India Ministry of Defence. We have amended the letter of credit, extending the expiration date to May 28, 2016.

As of December 31, 2015, we did not have any other off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources.

Recent Accounting Pronouncements

measure inventory at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments in ASU 2015-11 apply to inventory that is measured using the first-in, first-out or average cost methods. ASU 2015-11 amends some of the guidance in Topic 330 to more clearly articulate the requirements for the measurement and disclosure of inventory, but the clarifications are not intended to result in any changes in practice other than the change in the subsequent measurement guidance from the lower of cost or market to the lower of cost or net realizable value for inventory. There are no other substantive changes to the guidance on the measurement of inventory. This guidance is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, which is effective for our fiscal year beginning July 1, 2017, the first day of our 2018 fiscal year. We are currently evaluating the impact of this accounting guidance and do not expect any significant impact on our consolidated financial statements.

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain statements that are “forward-looking” within the meaning of the federal securities laws. These forward looking statements and other information are based on our beliefs as well as assumptions made by us using information currently available.

The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “will,” “should” and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events, are subject to certain risks, uncertainties and assumptions, and are not guaranties of future performance. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or using other similar expressions.

We are making investors aware that such forward-looking statements, because they relate to future events, are by their very nature subject to many important factors that could cause actual results to differ materially from those contemplated by the forward-looking statements contained in this Report. Important factors that could cause actual results to differ from our predictions include those discussed under this “Management’s Discussion and Analysis” and under “Risk Factors,” as well as those discussed under “Risk Factors,” “Management’s Discussion and Analysis” and “Business” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015. Although we have sought to identify the most significant risks to our business, we cannot predict whether, or to what extent, any of such risks may be realized, nor can there be any assurance that we have identified all possible issues which we might face. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic revisions based on actual experience and business developments, the impact of which may cause us to alter our marketing, capital expenditure or other budgets, which may in turn affect our financial position and results of operations. For all of these reasons, the reader is cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date hereof. We assume no responsibility to update any forward-looking statements as a result of new information, future events, or otherwise except as required by law. We urge readers to review carefully the risk factors described in this Quarterly Report, in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015 and in the other documents that we file with the Securities and Exchange Commission. You can read these documents at www.sec.gov.

Item 4.

Controls and Procedures

The certifications of our Chief Executive Officer and Chief Financial Officer attached as Exhibits 31.1 and 31.2 to this Quarterly Report on Form 10-Q include, in paragraph 4 of such certifications, information concerning our disclosure controls and procedures, and internal control over financial reporting. Such certifications should be read in conjunction with the information contained in this Item 4 for a more complete understanding of the matters covered by such certifications.

Disclosure Controls and Procedures.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2015. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the rules and forms of the Securities and Exchange Commission. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions to be made regarding required disclosure. It should be noted that any system of controls and procedures, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met and that management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

As a result of material weaknesses described in our Annual Report on Form 10-K for the year ended June 30, 2015, our Chief Executive Officer and Chief Financial Officer concluded that, we did not maintain effective internal control over financial reporting as of December 31, 2015 and further concluded that, as of such date, our disclosure controls and procedures were not effective at the reasonable assurance level.

Remediation

We are committed to remediating the material weaknesses identified in internal controls over financial reporting and have begun the process to remediate these material weaknesses, however the timing of completing our remediation efforts is uncertain. Our efforts will focus on instituting mitigating controls to address segregation of duties and undertake a thorough review of the finance functions position responsibilities and the hiring of additional staff; implement additional controls to address system access deficiencies; establish independent review and verification procedures for our vendor and customer master files; enhance the documentation to support review occurrences and approval procedures; and, commence regular periodic reviews of our internal controls over financial reporting with our Board of Directors and Audit Committee to address the inadequate risk oversight function and institute procedures to evaluate and report on risks to financial reporting, including the documentation and completion of a comprehensive risk assessment to identify all potential risk areas and evaluate the adequacy of our controls to mitigate these risks.

Changes in Internal Control Over Financial Reporting

During the three months ended December 31, 2015, we have implemented additional controls to address system access deficiencies and have begun instituting mitigating controls to address segregation of duty issues. There are no other changes that have materially affected, or is reasonably likely to materially affect our internal controls over financial reporting.

PART II.

OTHER INFORMATION

Item 1.

Legal Proceedings

We may, from time to time, be involved in other actual or potential proceedings that we consider to be in the normal course of our business. We do not believe that any of these proceedings will have a material adverse effect on our business. We are not a party to any other legal proceedings, other than ordinary routine litigation incidental to our business, which we believe will not have a material effect on our business, assets or results of operations.

Item 1A.

Risk Factors

Other than as set forth below, there have not been any material changes from the risk factors previously disclosed under Item 1A of our Annual Report on Form 10-K, for the fiscal year ended June 30, 2015.

We will be required to repay our secured borrowings on March 31, 2016.

As of February 5, 2016, our obligations to DMRJ under each of the six promissory notes and a revolving line of credit approximated $12,000,000, $12,000,000, $1,000,000 and $16,862,000, respectively. Further, as of February 5, 2016, our obligation to DMRJ for accrued interest under these instruments approximated $15,187,000.

If we are unable to repay these amounts as required, refinance our obligations to DMRJ, BAM and Montsant or negotiate extensions of these obligations, DMRJ, BAM and Montsant may seize our assets and we may be forced to file for protection under bankruptcy laws and to curtail or discontinue operations entirely.

We will require additional capital to fund operations and continue the development, commercialization and marketing of our product. Our failure to raise capital could have a material adverse effect on our business.

Management continually evaluates operating expenses and plans to increase sales and increase cash flow from operations. Despite our current sales, expense and cash flow projections and $3,084,000 in cash available from our line of credit with DMRJ, at February 5, 2016, to fund our operations and continue the development, commercialization and marketing of our products will require that we extend our credit facilities with DMRJ, BAM and Montsant. There can be no assurance that DMRJ will continue to make advances under our revolving line of credit. Our failure to achieve our projections and/or obtain sufficient additional capital on acceptable terms would have a material adverse effect on our liquidity and operations and could require us to file for protection under bankruptcy laws. These conditions raise substantial doubt as to our ability to continue as a going concern.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended December 31, 2015, we issued 330,000 shares of common stock, having a value of approximately $248,000, to two advisors, in consideration of services rendered to us under two advisory and consulting services agreements. The issuance of these shares was exempt from registration under the Securities Act pursuant to an exemption provided by Section 4(2) of the Securities Act.

Item 6.

Exhibits


Exhibit No.		Description
10.1		Accounts Receivable Purchase Agreement, dated as of December 11, 2015, between Implant Sciences Corporation and Republic Capital Access, LLC (incorporated herein by reference Exhibit 10.1 to Implant Sciences Corporation’s Current Report on Form 8-K dated December 22, 2015 and filed on January 4, 2016).
10.2		Lien Release Agreement, dated as of December 17, 2015, between Republic Capital Access, LLC and DMRJ Group, LLC (incorporated herein by reference to Exhibit 10.2 to Implant Sciences Corporation’s Current Report on Form 8-K dated December 22, 2015and filed on January 4, 2016).
10.3		Lien Release and Amendment Agreement, dated as of December 22, 2015, between Republic Capital Access, LLC, BAM Administrative Services, LLC and Implant Sciences Corporation (incorporated herein by reference to Exhibit 10.3 to Implant Sciences Corporation’s Current Report on Form 8-K dated December 22, 2015 and filed on January 4, 2016).
10.4		Amendment No. 1 to Employment Agreement between Implant Sciences Corporation and William McGann, dated January 6, 2016.*
10.5		Amendment No. 1 to Employment Agreement between Implant Sciences Corporation and Darryl Jones, dated January 6, 2016.*
10.6		Amendment No. 1 to Employment Agreement between Implant Sciences Corporation and Todd Silvestri, dated January 6, 2016.*
10.7		Amendment No. 1 to Employment Agreement between Implant Sciences Corporation and Brenda Baron, dated January 6, 2016.*
10.8		Amendment No. 1 to Employment Agreement between Implant Sciences Corporation and Roger Deschenes, dated January 6, 2016.*
10.9		Employment Agreement between Implant Sciences Corporation and Robert Liscouski, dated December 15, 2015.*
31.1		Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of the Chief Executive Officer Pursuant to 18 U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2		Certification of the Chief Financial Officer Pursuant to 18 U.S.C. 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS		XBRL Instance Document.
101.SCH		XBRL Taxonomy Extension Schema Document.
101.CAL		XBRL Taxomony Extension Calculation Linkbase Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

Indicates a management contract of compensatory plan or arrangement.

In accordance with Item 601(b)(32)(ii) of Regulation S-K, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed to be “filed” for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	Implant Sciences Corporation
	By:	/s/ William J. McGann
		William J. McGann Chief Executive Officer (Principal Executive Officer)

	By:	/s/ Roger P. Deschenes
		Roger P. Deschenes Vice President, Finance and Chief Financial Officer (Principal Financial Officer and Chief Accounting Officer)

Dated: February 16, 2016

Exhibit 10.4

AMENDMENT NO. 1 TO AMENDED

AND RESTATED EMPLOYMENT AGREEMENT

THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Amendment”), dated effective as of January 6, 2016 (the “Effective Date”), is by and between Implant Sciences Corporation (the “Company”), a Massachusetts corporation, and William McGann (“Executive”).

WHEREAS, the Company and Executive are parties to that certain Amended and Restated Employment Agreement, dated January 16, 2015 (the “Employment Agreement”); and

WHEREAS, the Company and the Executive desire to amend the Employment Agreement on the terms and conditions set forth herein in accordance with Section 8 of the Employment Agreement.

NOW THEREFORE, for good and valuable consideration, the receipt, and legal adequacy of which is hereby acknowledged, the parties, intending to be legally bound, hereby agree to amend the Employment Agreement as of the Effective Date as follows:

Section 3.1 of the Employment Agreement is hereby amended by inserting the word “similarly” before the word “reduced” at the end of the section.

Section 5.2 of the Employment Agreement is hereby amended by deleting the phrase “Executive executes a release satisfactory to the Company in favor of the Company” and replacing it with the phrase “Executive executes a release in favor of the Company substantially in the form annexed hereto as Exhibit A, not later than 30 days after Executive’s employment terminates.” The Employment Agreement is further amended by the addition of the attached Exhibit “A.”

Section 5.5 of the Employment Agreement, defining “Good Reason” for Executive to resign, is hereby amended by adding the following text immediately before that section’s last sentence:

In the event Executive resigns for Good Reason within twelve (12) months after a Change of Control or acquisition, as defined in (d) or (e) above, Executive shall receive, in addition to any severance to which he is entitled under § 5.2 of the Employment Agreement as amended, an additional sum equal to twenty-four (24) months of his base salary then in effect.

[Signature page follows]

IN WITNESS WHEREOF, each of the Company and Executive has executed this Amendment as of the date first above written.

IMPLANT SCIENCES CORPORATION

By:

/s/ Roger Deschenes

Name: Roger Deschenes

Title: Chief Financial Officer

Date Executed: January 6, 2016

/s/ William McGann

William McGann, Ph.D.

Date Executed: January 6, 2016

[Signature page of Amendment No. 1 to Amended and Restated Employment Agreement]

Exhibit A

General Release of Claims

Your Release of Claims. By signing this Agreement, you hereby agree and acknowledge that, for good and valuable consideration, you are waiving your right to assert any and all forms of legal claims against the Company¹²/ of any kind whatsoever, whether known or unknown, arising from the beginning of time through the date you execute this Agreement (the “Execution Date”). Except as set forth below, your waiver and release herein is intended to bar any form of legal claim, complaint or any other form of action (jointly referred to as “Claims”) against the Company seeking any form of relief including, without limitation, equitable relief (whether declaratory, injunctive or otherwise), the recovery of any damages, or any other form of monetary recovery whatsoever (including, without limitation, back pay, front pay, compensatory damages, emotional distress damages, punitive damages, attorneys’ fees and any other costs) against the Company, for any alleged action, inaction or circumstance existing or arising through the Execution Date.

Without limiting the foregoing general waiver and release, you specifically waive and release the Company from any Claim arising from or related to your prior employment relationship with the Company or the termination thereof, including, without limitation:

Claims under any state or federal discrimination, fair employment practices or other employment related statute, regulation or executive order (as they may have been amended through the Execution Date) prohibiting discrimination or harassment based upon any protected status including, without limitation, race, national origin, age, gender, marital status, disability, veteran status or sexual orientation. Without limitation, specifically included in this paragraph are any Claims arising under the Age Discrimination in Employment Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Equal Pay Act, the Americans With Disabilities Act and any similar Federal and state statute.

Claims under any other state or federal employment related statute, regulation or executive order (as they may have been amended through the Execution Date) relating to wages, hours or any other terms and conditions of employment.

Claims under any state or federal common law theory including, without limitation, wrongful discharge, breach of express or implied contract, promissory estoppel, unjust enrichment, breach of a covenant of good faith and fair dealing, violation of public policy, defamation, interference with contractual relations, intentional or negligent infliction of emotional distress, invasion of privacy, misrepresentation, deceit, fraud or negligence.

¹¹^/

For purposes of this Agreement, the Company includes the Company and any of its divisions, affiliates (which means all persons and entities directly or indirectly controlling, controlled by or under common control with the Company), subsidiaries and all other related entities, and its and their directors, officers, employees, trustees, agents, successors and assigns.

Any other Claim arising under state or federal law.

You acknowledge and agree that, but for providing this waiver and release, you would not be receiving the economic benefits being provided to you under the terms of this Agreement. You further acknowledge that this release does not waive any claims you cannot by law waive and does not release any claims that arise after its execution.

It is the Company’s desire and intent to make certain that you fully understand the provisions and effects of this Agreement. To that end, you have been advised and given the opportunity to consult with legal counsel for the purpose of reviewing the terms of this Agreement. Also, because you are over the age of 40, the Age Discrimination in Employment Act (“ADEA”), which prohibits discrimination on the basis of age, allows you at least twenty-one (21) days to consider the terms of this Agreement. ADEA also allows you to rescind your assent to this Agreement if, within seven (7) days after you sign this Agreement, you deliver by hand or send by mail (certified, return receipt and postmarked within such 7 day period) a notice of rescission to the Company. The eighth day following your signing of this Agreement is the Effective Date.

Also, consistent with the provisions of Federal law, nothing in this release shall be deemed to prohibit you from challenging the validity of this release under the discrimination laws (the “Federal Discrimination Laws”) or from filing a charge or complaint of employment-related discrimination with the Equal Employment Opportunity Commission (“EEOC”) or any state fair employment practices agency, or from participating in any investigation or proceeding conducted by the EEOC or any state fair employment practices agency. Further, nothing in this release or Agreement shall be deemed to limit the Company’s right to seek immediate dismissal of such charge or complaint on the basis that your signing of this Agreement constitutes a full release of any individual rights under the Federal Discrimination Laws, or to seek restitution to the extent permitted by law of the economic benefits provided to you under this Agreement in the event that you successfully challenge the validity of this release and prevail in any claim under the Federal Discrimination Laws.

By: /s/ William McGann

Executive: William McGann, Ph.D.

Date signed: January 6, 2016

Exhibit 10.5

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment”), dated effective as of January 6, 2016 (the “Effective Date”), is by and between Implant Sciences Corporation (the “Company”), a Massachusetts corporation, and Darryl Jones (“Executive”).

WHEREAS, the Company and Executive are parties to that certain Employment Agreement, dated March 7, 2012 (the “Employment Agreement”); and

WHEREAS, the Company and the Executive desire to amend the Employment Agreement on the terms and conditions set forth herein in accordance with Section 8 of the Employment Agreement.

Section 3.1 of the Employment Agreement is hereby amended by inserting the word “similarly” before the word “reduced” at the end of the section.

Section 5.5 of the Employment Agreement, defining “Good Reason” for Executive to resign, is hereby amended by adding the following text immediately before that section’s last sentence:

[Signature page follows]

IN WITNESS WHEREOF, each of the Company and Executive has executed this Amendment as of the date first above written.

IMPLANT SCIENCES CORPORATION

By:

/s/ William McGann

William McGann, Ph.D.

Title: Chief Executive Officer

Date Executed: January 6, 2016

/s/ Darryl Jones

Darryl Jones, Ph. D.

Date Executed: January 6, 2016

[Signature page of Amendment No. 1 to Employment Agreement]

Exhibit A

General Release of Claims

¹¹^/

Any other Claim arising under state or federal law.

By:

/s/ Darryl Jones

Executive: Darryl Jones, Ph.D.

Date signed: January 6, 2016

Exhibit 10.6

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

WHEREAS, the Company and Executive are parties to that certain Employment Agreement, dated March 9, 2015 (the “Employment Agreement”); and

WHEREAS, the Company and the Executive desire to amend the Employment Agreement on the terms and conditions set forth herein in accordance with Section 8 of the Employment Agreement.

Section 3.1 of the Employment Agreement is hereby amended by inserting the word “similarly” before the word “reduced” at the end of the section.

Section 5.2 of the Employment Agreement is hereby amended by substituting the word “twelve” for the word “six” where the Employment Agreement states that “the Company shall continue to pay to Executive the annual Base Salary in effect immediately prior to such termination for the six month period following Executive’s last day of employment.”

Section 5.5 of the Employment Agreement, defining “Good Reason” for Executive to resign, is hereby amended by adding, after subsection (c), new subsections (d) and (e) and other provisions, set forth below:

Exchange Act of 1934, as amended (the “Exchange Act”)), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of the then outstanding shares of voting stock of the Company (the “Voting Stock”); provided, however, that any acquisition by the Company or its subsidiaries, or any employee benefit plan (or related trust) of the Company or its subsidiaries of (i) 50% or more of the then outstanding Voting Stock, or (ii) Voting Stock which has the effect of increasing the percentage of Voting Stock owned by any such individual, entity or group to 50% or more of the then outstanding Voting Stock, shall not constitute a Change of Control. In the event Executive resigns for Good Reason within 12 months after a Change of Control or acquisition, as defined in (d) or (e) above, Executive shall receive, in addition to any severance to which he is entitled under § 5.2 of the Employment Agreement as amended, an additional sum equal to twelve (12) months of his base salary then in effect.

IN WITNESS WHEREOF, each of the Company and Executive has executed this Amendment as of the date first above written.

IMPLANT SCIENCES CORPORATION

By:

/s/ William McGann

Name: William McGann, Ph.D.

Title: Chief Executive Officer

Date Executed: January 6, 2016

/s/ Todd Silvestri

Todd Silvestri

Date Executed: January 6, 2016

Exhibit A

General Release of Claims

¹¹^/

Any other Claim arising under state or federal law.

By:

/s/ Todd Silvestri

Executive: Todd Silvestri

Date signed: January 6, 2016

Exhibit 10.7

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

WHEREAS, the Company and Executive are parties to that certain Employment Agreement, dated March 9, 2015 (the “Employment Agreement”); and

WHEREAS, the Company and the Executive desire to amend the Employment Agreement on the terms and conditions set forth herein in accordance with Section 8 of the Employment Agreement.

Section 3.1 of the Employment Agreement is hereby amended by inserting the word “similarly” before the word “reduced” at the end of the section.

(d) a “Change of Control” of the Company, as that term is defined in the Control Plan adopted by the Company and as may be amended from time to time; or (e), the acquisition (other than an acquisition directly from the Company) by any individual, entity or group (within the meaning of Section l3(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or

more of the then outstanding shares of voting stock of the Company (the “Voting Stock”); provided, however, that any acquisition by the Company or its subsidiaries, or any employee benefit plan (or related trust) of the Company or its subsidiaries of (i) 50% or more of the then outstanding Voting Stock, or (ii) Voting Stock which has the effect of increasing the percentage of Voting Stock owned by any such individual, entity or group to 50% or more of the then outstanding Voting Stock, shall not constitute a Change of Control. In the event Executive resigns for Good Reason within twelve (12) months after a Change of Control or acquisition, as defined in (d) or (e) above, Executive shall receive, in addition to any severance to which she/he is entitled under § 5.2 of the Employment Agreement as amended, an additional sum equal to twelve (12) months of his/her base salary then in effect.

IN WITNESS WHEREOF, each of the Company and Executive has executed this Amendment as of the date first above written.

IMPLANT SCIENCES CORPORATION

By:

/s/ William McGann

Name: William McGann, Ph.D.

Title: Chief Executive Officer

Date Executed: January 6, 2016

/s/ Brenda Baron

Brenda Baron

Date Executed: January 6, 2016

Exhibit A

General Release of Claims

¹¹^/

Any other Claim arising under state or federal law.

By:

/s/ Brenda Baron

Executive: Brenda Baron

Date signed: January 6, 2016

Exhibit 10.8

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

WHEREAS, the Company and Executive are parties to that certain Employment Agreement, dated September 16, 2015 (the “Employment Agreement”); and

WHEREAS, the Company and the Executive desire to amend the Employment Agreement on the terms and conditions set forth herein in accordance with Section 8 of the Employment Agreement.

Section 3.1 of the Employment Agreement is hereby amended by inserting the word “similarly” before the word “reduced” at the end of the section.

Stock”); provided, however, that any acquisition by the Company or its subsidiaries, or any employee benefit plan (or related trust) of the Company or its subsidiaries of (i) 50% or more of the then outstanding Voting Stock, or (ii) Voting Stock which has the effect of increasing the percentage of Voting Stock owned by any such individual, entity or group to 50% or more of the then outstanding Voting Stock, shall not constitute a Change of Control. In the event Executive resigns for Good Reason within twelve (12) months after a Change of Control or acquisition, as defined in (d) or (e) above, Executive shall receive, in addition to any severance to which he is entitled under § 5.2 of the Employment Agreement as amended, an additional sum equal to twelve (12) months of his base salary then in effect.

IN WITNESS WHEREOF, each of the Company and Executive has executed this Amendment as of the date first above written.

IMPLANT SCIENCES CORPORATION

By:

/s/ William McGann

Name: William McGann, Ph.D.

Title: Chief Executive Officer

Date Executed: January 6, 2016

/s/ Roger Deschenes

Roger Deschenes

Date Executed: January 6, 2016

Exhibit A

General Release of Claims

¹¹^/

Any other Claim arising under state or federal law.

By: /s/ Roger Deschenes

Executive: Roger Deschenes

Date signed: January 6, 2016

Exhibit 10.9

EMPLOYMENT AGREEMENT

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of this 15th day of December 2015, between Robert Liscouski (“Executive”) and Implant Sciences Corporation (the “Company”), a Massachusetts corporation.

WHEREAS, the Company desires that for the foreseeable future the Executive will serve as the Company’s President as well as a member of the Board of Directors and the Executive is willing to continue to serve in the foregoing positions on the terms and conditions set forth in this Agreement;

NOW, THEREFORE in consideration of the mutual covenants and promises contained herein and other good and valuable considerations, the sufficiency of which is hereby acknowledged, the Company and the Executive hereby agree as follows:

1. Effective Date and Term of Employment. As of the first date stated above (“Effective Date”), the Executive shall serve as the Company’s President. The Company will employ Executive as President and Executive agrees to work for the Company, at its Wilmington, Massachusetts facility, to perform the duties and responsibilities inherent in such position, and such other duties and responsibilities as the Company shall from time to time assign to Executive.

2. Duties and Responsibilities. The Executive agrees to work for the Company as its President performing all of the duties and responsibilities inherent in such position. As the President the Executive shall report to the Company’s CEO and Board of Directors and shall be subject to the supervision thereof, and Executive shall have such authority as is delegated by the Board, which authority shall be sufficient for Executive to perform all of the duties of the office referenced herein. The Executive shall devote the Executive’s full business time and reasonable best efforts in the performance of the foregoing services. Subject to the restrictions set forth in Section 6.4, Executive may accept other board memberships or service with other charitable organizations that are not in conflict with Executive’s primary responsibilities and obligations to the Company.

3. Compensation and Benefits.

3.1 Salary. The Company has paid, prior to the Effective Date hereof, and shall continue to pay, Executive a base salary of $11,538.46 every two weeks (i.e., at an annualized rate of $300,000 per year), payable in accordance with the Company’s customary payroll practices (the “Base Salary”). The Base Salary thereafter shall be subject to annual review and adjustment, as determined by the Board (or the Compensation Committee of the Board) in its sole discretion, provided, however, that the Base Salary may not be decreased without the Executive’s consent unless the compensation payable to all executives of the Company is also similarly reduced.

3.2 Annual Incentive. For the fiscal year ending June 30, 2015, Executive will receive a sign on cash bonus in the amount $200,000 (two hundred thousand dollars). For the fiscal year ending June 30, 2016 and in subsequent fiscal years, Executive will be eligible to receive an

annual cash bonus in an amount up to $150,000, subject to Executive achieving any performance milestones that are established and approved by the Board of Directors within 60 days following the beginning of such fiscal year. The bonus(es), if payable, shall be calculated and paid within 30 days after the end of the fiscal year in which such bonus was earned; provided, however, that the Company may delay the calculation and payment of any portion of such bonus which is based on the attainment of a revenue, earnings or similar milestone until the completion of the audit of the Company’s financial statements for the fiscal year in question.

3.3 Long-Term Incentives. The Company previously granted the Executive certain stock options in connection with his service as a consultant to the Company (“Initial Options”), and that grant was consistent with the Company’s 2004 Stock Option Plan (“2004 SOP”). The Initial Options are now fully-vested and exercisable by Executive. In September 2012, and in March and July 2014, the Company granted the Executive additional stock options pursuant to the 2004 SOP (“At Risk Options”), which options are also subject to the Change in Control Plan adopted in September 2012 (“Control Plan”). The Executive’s 2012 At Risk Options are now fully vested and exercisable; the 2014 At Risk Options are partially vested and exercisable as of the Effective Date hereof. Executive and Company acknowledge and agree that the Executive’s Initial and At Risk Options are and shall be governed in all respects by the 2004 SOP, as the same may be amended from time to time and by the Control Plan, as amended from time to time; provided however that notwithstanding anything to the contrary in the 2004 SOP or the Control Plan, as amended, in the event a Change in Control occurs, as such term is defined in the Control Plan, then the latest date(s) by which Executive may exercise his Initial and At Risk Options shall not accelerate but shall remain as stated in the respective stock option grants unless the Executive consents in writing to a shorter time period.

3.4 Fringe Benefits. Executive shall be entitled to participate in all bonus and benefit programs that the Company establishes and makes available to its executive employees, if any, to the extent that Executive’s position, tenure, salary, age, health and other qualifications make Executive eligible to participate, including, but not limited to health care plans, short and long term disabilities plans, life insurance plans, retirement plans, and all other benefit plans from time to time in effect. Executive shall also be entitled to take four (4) weeks of fully paid vacation in accordance with Company policy.

3.5 Reimbursement of Certain Expenses. Executive shall be reimbursed for such reasonable and necessary business expenses incurred by Executive while Executive is employed by the Company, which are directly related to the furtherance of the Company’s business, including compensation under the Company’s standard policies if Executive uses his personal vehicle for Company business where such business is more than one hundred fifty (150) miles from the Company’s main offices or Executive’s home, wherever such trip commences. The Executive must submit any request for reimbursement no later than ninety (90) days following the date that such business expense is incurred in accordance with the Company’s reimbursement policy regarding same and business expenses must be substantiated by appropriate receipts and documentation. The Company may request additional documentation or a further explanation to substantiate any business expense submitted for reimbursement, and retains the discretion to approve or deny a request for reimbursement. If a business expense reimbursement is not exempt from Section 409A of the Code, any reimbursement in one calendar year shall not affect the amount that may be reimbursed in any other calendar year and a reimbursement (or right thereto)

may not be exchanged or liquidated for another benefit or payment. Any business expense reimbursements subject to Section 409A of the Code shall be made no later than the end of the calendar year following the calendar year in which such business expense is incurred by the Executive.

3.6 Indemnification. The Company shall continue to indemnify Executive to the fullest extent permitted under applicable law, the Company’s Articles of Organization and the Company’s By-laws, each as they may be amended from time to time. The Executive shall be insured under the Company’s Directors’ and Officers’ liability policy in the same manner as other senior executives of the Company for as long as Executive is an officer or director of the Company and as long as the Company maintains such policy in force. Such indemnity and insurance shall survive the termination of Executive’s employment by the Company.

Termination of Employment Period. Executive’s employment under the terms of this agreement may terminate upon the occurrence of any of the following:

4.1

Termination for Cause. At the election of the Company, for “Cause,” upon written notice by the Company to Executive. For the purposes of this Section, “Cause” for termination shall be deemed to exist upon the occurrence of any of the following:

(a)

Executive’s conviction or entry of nolo contendere to any felony or a crime involving moral turpitude, fraud or embezzlement of Company property; or

(b)

Executive’s dishonesty, gross negligence or gross misconduct that is materially injurious to the Company or material failure to perform her/his duties under this Agreement which has not been cured by Executive within 10 days after he/she shall have received written notice from the Company stating with reasonable specificity the nature of such failure to perform; or

(c)

Executive’s illegal use or abuse of drugs, alcohol, or other related substances that is materially injurious to the Company.

4.2

Voluntary Termination by the Company. At the election of the Company, without Cause.

4.3

Death or Disability. Upon the death or disability of Executive. As used in this Agreement, “disability” shall occur when Executive, due to a physical or mental disability, for a period of 90 days in the aggregate whether or not consecutive, during any 360-day period, is unable to perform the services contemplated under this Agreement.

4.4

Termination for Good Reason. Subject to the notice and cure periods set forth in Section 5.5, at the election of Executive for “Good Reason” (as defined below), upon written notice by the Executive to the Company.

4.5

Voluntary Termination by Executive. At the election of Executive, without Good Reason, upon not less than 30 days prior written notice by him/her to the Company.

Effect of Termination.

5.1

Termination for Cause, at the Election of Executive, or at Death or Disability. In the event that Executive’s employment is terminated for Cause, the Company shall have no further obligations under this Agreement other than to pay to Executive Base Salary and accrued vacation through the last day of Executive’s actual employment by the Company. In the event that Executive’s employment is terminated upon Executive’s death or disability, or at the election of Executive, the Company shall have no further obligations under this Agreement other than (i) to pay to Executive, in a single lump sum upon such termination, Base Salary and accrued vacation through the last day of Executive’s actual employment by the Company and (ii) to pay to Executive, in a single lump sum, a pro rata portion of any bonus (to the extent earned prior to such termination) for the fiscal year in which termination occurs, pursuant to Section 3.2.

5.2

Voluntary Termination by the Company, or for Good Reason. In the event that Executive’s employment is terminated during the term of this Agreement without Cause, or by Executive’s resignation for Good Reason, and Executive executes a release in favor of the Company substantially in the form annexed hereto as Exhibit A, not later than 30 days after Executive’s employment terminates, and the period in which Executive is entitled to revoke such release has expired without any such revocation, then the Company shall continue to pay to Executive the annual Base Salary in effect immediately prior to such termination for the twelve-month period following Executive’s last day of employment. In addition, the Company shall continue Executive’s coverage under and its contributions towards Executive’s health care, dental, and life insurance benefits on the same basis as immediately prior to the date of termination, except as provided below, for the six-month period following Executive’s last day of employment. In addition to the foregoing amounts, the Company shall pay Executive in a single lump sum, a pro rata portion of any bonus (to the extent earned prior to such termination) for the year in which termination occurs, pursuant to Section 3.2. Notwithstanding the foregoing, subject to any overriding laws, the Company shall not be required to provide any health care, dental, or life insurance benefit otherwise receivable by Executive if Executive is actually covered or becomes covered by an equivalent benefit (at the same cost to Executive, if any) from another source. Any such benefit made available to Executive shall be reported to the Company.

5.3

Notwithstanding any other provision of this Amended Agreement with respect to the timing of payments under Section 5, if, at the time of the Executive’s termination, the Executive is deemed to be a “specified employee” of the Company within the meaning of Section 409A(a)(2)(B)(i) of the Code, then only to the extent necessary to comply with the requirements of Section 409A of the Code, any payments to which the Executive may become entitled under Section 5 which are subject to Section 409A of the Code (and not otherwise exempt from its application) will be withheld until the first business day of the seventh month following the date of termination, at which time the Executive shall be paid an aggregate amount equal to six months of payments otherwise due to the Executive under the terms of Section 5, as applicable. After the first business day of the seventh month following the date of termination and continuing each month thereafter, the Executive shall be paid the regular payments otherwise due to the Executive in accordance with the terms of Section 5, as thereafter applicable.

5.4

Upon Executive’s termination without Cause during the term of this Agreement, or as a result of Executive’s resignation for Good Reason during the term of this Agreement, all stock options granted by the Company and then held by Executive shall be accelerated and become fully vested and exercisable as of the date of Executive’s termination.

5.5

As used in this Agreement, “Good Reason” means, without Executive’s written consent, (a) a “material diminution” (as such term is used in Section 409A of the Code) of the duties assigned to Executive (provided, however, that no termination of Executive’s service as a member of the Board, regardless of the reason therefore, shall constitute a “material diminution” of Executive’s duties for purposes of this Section 5.5); or (b) a material reduction in Base Salary or other benefits (other than a reduction or change in benefits generally applicable to all executive employees of the Company); or (c) relocation to an office more than 50 miles further from Executives current residence in Massachusetts than the Company’s current location in the greater Boston area is located from such residence; or (d) a “Change of Control” of the Company, as that term is defined in the Control Plan; or (e), the acquisition (other than an acquisition directly from the Company) by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 50% or more of the then outstanding shares of voting stock of the Company (the “Voting Stock”); provided, however, that any acquisition by the Company or its subsidiaries, or any employee benefit plan (or related trust) of the Company or its subsidiaries of (i) 50% or more of the then outstanding Voting Stock, or (ii) Voting Stock which has the effect of increasing the percentage of Voting Stock owned by any such individual, entity or group to 50% or more of the then outstanding Voting Stock, shall not constitute a Change of Control. In the event Executive resigns for Good Reason within twelve (12) months after a Change of Control or acquisition, as defined in (d) or (e) above, Executive shall receive, in addition to any severance to which he/she is entitled under § 5.2 of the Employment Agreement as amended, an additional sum equal to twelve (12) months of his/her base salary then in effect. Notwithstanding the occurrence of any of the events enumerated in this Section 5.5, no event or condition shall be deemed to constitute Good Reason unless (i) Executive reports the event or condition which the Executive believes to be Good Reason to the Board, in writing, within 45 days of such event or condition occurring and (ii) within 30 days after the Executive provides such written notice of Good Reason, the Company has failed to fully correct such Good Reason and to make the Executive whole for any such losses.

5.6

The provisions of this Section 5 and the payments provided hereunder are intended to be exempt from or to comply with the requirements of Section 409A of the Code, and shall be interpreted and administered consistent with such intent. To the extent required for compliance with Section 409A, references in this Agreement to a “termination of employment” shall mean a “separation of service” as defined by Section 409A. It is further intended that each installment of the payments provided hereunder shall be treated as a separate “payment” for purposes of Section 409A. Neither the Company nor Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A.

Nondisclosure and Noncompetition.

6.1

Proprietary Information.

(a)

Executive agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning the Company’s business or financial affairs (collectively, “Proprietary Information”) is and shall be the exclusive property of the Company. By way of illustration, but not limitation, Proprietary Information may include inventions, products, processes, methods, techniques, formulas, designs, drawings, slogans, tests, logos, ideas, practices, projects, developments, plans, research data, financial data, personnel data, computer programs and codes, and customer and supplier lists. Executive will not disclose any Proprietary Information to others outside the Company except in the performance of his/her duties or use the same for any unauthorized purposes without written approval by an officer of the Company, either during or after his employment, unless and until such Proprietary Information has become public knowledge or generally known within the industry without fault by Executive, or unless otherwise required by law.

(b)

Executive agrees that all files, letters, memoranda, reports, records, data, sketches, drawings, laboratory notebooks, program listings, or other written, photographic, electronic or other material containing Proprietary Information, whether created by Executive or others, which shall come into his custody or possession, shall be and are the exclusive property of the Company to be used by Executive only in the performance of her/his duties for the Company.

(c)

Executive agrees that his/her obligation not to disclose or use information, know-how and records of the types set forth in paragraphs (a) and (b) above, also extends to such types of information, know-how, records and tangible property of subsidiaries and joint ventures of the Company, customers of the Company or suppliers to the Company or other third parties who may have disclosed or entrusted the same to the Company or to Executive in the course of the Company’s business.

6.2

Inventions.

(a)

Disclosure. Executive shall disclose promptly to an officer or to attorneys of the Company in writing any idea, invention, work of authorship, whether patentable or un-patentable, copyrightable or un-copyrightable, including, but not limited to, any computer program, software, command structure, code, documentation, compound, genetic or biological material, formula, manual, device, improvement, method, process, discovery, concept, algorithm, development, secret process, machine or contribution (any of the foregoing items hereinafter referred to as an “Invention”) Executive may conceive, make, develop or work on, in whole or in part, solely or jointly with others. The disclosure required by this Section applies (a) to any invention related to the general line of business engaged in by the Company or to which the Company planned to enter during the period of Executive’s employment with the Company and for one year thereafter; (b) with respect to all Inventions whether or not they are conceived, made, developed or worked on by Executive during Executive’s regular hours of employment with the Company; (c) whether or not the Invention was made at the suggestion of the Company; and (d) whether or not the Invention was reduced to drawings, written description, documentation, models or other tangible form.

(b)

Assignment of inventions to Company; Exemption of Certain Inventions. Executive hereby assigns to the Company without royalty or any other further

consideration Executive’s entire right, title and interest in and to all Inventions which Executive conceives, makes, develops or works on during employment and for one year thereafter, except as limited by 6.2(a) above and those Inventions that Executive develops entirely on Executive’s own time after the date of this Agreement without using the Company’s equipment, supplies, facilities or trade secret information unless those Inventions either (a) relate at the time of conception or reduction to practice of the Invention to the Company's business, or actual or demonstrably anticipated research or development of the Company; or (b) result from any work performed by Executive for the Company.

(c)

Records. Executive will make and maintain adequate and current written records of all Inventions. These records shall be and remain the property of the Company.

(d)

Patents. Executive will assist the Company in obtaining, maintaining and enforcing patents and other proprietary rights in connection with any Invention covered by Section 6.2. Executive further agrees that his obligations under this Section shall continue beyond the termination of his employment with the Company, but if he is called upon to render such assistance after the termination of such employment, he shall be entitled to a fair and reasonable rate of compensation for such assistance. Executive shall, in addition, be entitled to reimbursement of any expenses incurred at the request of the Company relating to such assistance.

6.3 Prior Contracts and Inventions; Information Belonging to Third Parties. Executive represents that there are no contracts to assign Inventions between any other person or entity and Executive. Executive further represents that (a) Executive is not obligated under any consulting, employment or other agreement which would affect the Company’s rights or my duties under this Agreement, (b) there is no action, investigation, or proceeding pending or threatened, or any basis therefor known to me involving Executive’s prior employment or any consultancy or the use of any information or techniques alleged to be proprietary to any former employer, and (c) the performance of Executive’s duties as an employee of the Company will not breach, or constitute a default under any agreement to which Executive is bound, including, without limitation, any agreement limiting the use or disclosure of proprietary information acquired in confidence prior to engagement by the Company. Executive will not, in connection with Executive’s employment by the Company, use or disclose to the Company any confidential, trade secret or other proprietary information of any previous employer or other person to which Executive is not lawfully entitled.

6.4

Noncompetition and Non-solicitation.

(a)

During Executive’s employment with the Company and for a period of 12 months after the termination of Executive’s employment with the Company for any reason or for no reason, Executive will not directly or indirectly, absent the Company’s prior written approval, render services of a business, professional or commercial nature to any other person or entity in the area of trace explosives detection or such other services or products provided by the Company at the time employment terminates in any geographical area where the Company does business at the time this covenant is in effect, whether such services are for compensation or otherwise, whether alone or in conjunction with others, as an employee, as a partner, or as a shareholder (other than as the holder of not more than 1% of the combined voting

power of the outstanding stock of a public company), officer or director of any corporation or other business entity, or as a trustee, fiduciary or in any other similar representative capacity.

(b)

During the Executive’s employment with the Company and for a period of 12 months after the termination of Executive’s employment for any reason or for no reason, Executive will not, directly or indirectly, recruit, solicit or induce, or attempt to recruit, solicit or induce any employee or employees of the Company to terminate their employment with, or otherwise cease their relationship with, the Company.

(c)

During the Executive’s employment with the Company and for a period of 12 months after termination of Executive’s employment for any reason or for no reason, Executive will not, directly or indirectly, contact, solicit, divert or take away, or attempt to solicit, contact, divert or take away, the business or patronage of any of the clients, customers or accounts, or prospective clients, customers or accounts, of the Company.

6.5

Interpretation of Agreement. If any restriction set forth in this Section is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.

6.6

Restrictions Necessary. The restrictions contained in this Section are necessary for the protection of the business, proprietary information, and goodwill of the Company and are considered by Executive to be reasonable for such purpose. Executive agrees that any breach of this Section will cause the Company substantial and irrevocable damage and therefore, in the event of any such breach, in addition to such other remedies which may be available, the Company shall have the right to seek specific performance and injunctive relief. The prevailing party shall be entitled to recover its reasonable attorneys’ fees in such an action. In addition, the Company’s obligation to pay Executive the amount set forth in Section 5.2 or 5.3 shall terminate in the event Executive materially breaches any terms and conditions in Section 6.

Entire Agreement. This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements and understandings, whether written or oral relating to the subject matter of this Agreement between the Company and the Executive. For the avoidance of doubt, however, this Agreement is in addition to, and shall not supersede any stock option agreement between the Company and Executive.

Amendment. This Agreement may be amended or modified only by a written instrument executed by both the Company and Executive.

Arbitration. All disputes concerning compliance with or the interpretation of this Agreement, or any other aspect of Executive’s employment with the Company or the termination of that employment, shall be resolved by a single arbitrator under the Employment Dispute Rules then obtaining of the American Arbitration Association. The decision of the arbitrator shall be final and binding. Notwithstanding the foregoing, any claims by the Company concerning Executive’s compliance with the Nondisclosure and Noncompetition provisions of this Agreement are excluded from the scope of this Arbitration provision and may be brought

in any court of competent jurisdiction. This Agreement shall be construed, interpreted and enforced in accordance with the laws of the Commonwealth of Massachusetts without regard to principles of conflicts of laws thereunder.

10.

Notices. Any notice or other communication required or permitted by this Agreement to be given to a party shall be in writing and shall be deemed given if delivered personally or by commercial messenger or courier service, or mailed by U.S. registered or certified mail (return receipt requested), or sent via facsimile (with receipt of confirmation of complete transmission) to the party at the party's last known address or facsimile number or at such other address or facsimile number as the party may have previously specified by like notice. If by mail, delivery shall be deemed effective three business days after mailing in accordance with this Section.

11.

Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns, including any corporation into which the Company may be merged or which may succeed to its assets or business, provided, however, that the obligations of Executive are personal and shall not be assigned by her/him.

12.

Miscellaneous.

12.1

No Waiver. No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right on any other occasion.

12.2

Severability. In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.

12.3

Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument and facsimile signatures delivered by fax or e-mail transmission shall be treated as originals.

[Signature page follows]

IN WITNESS WHEREOF, each of the Company and Executive has executed this Amendment as of the date first above written.

IMPLANT SCIENCES CORPORATION

By:

/s/ William McGann

Name: William McGann, Ph.D.

Title: Chief Executive Officer

Date Executed: December 15, 2015

/s/ Robert Liscouski

Robert Liscouski

Date Executed: December 15, 2015

[Signature page for employment agreement]

Exhibit A

General Release of Claims

¹¹^/

Any other Claim arising under state or federal law.

By: /s/ Robert Liscouski

Executive:

Date signed: December 15, 2015

Exhibit 31.1

CERTIFICATION

I, William J. McGann, hereby certify that:

I have reviewed this Quarterly Report on Form 10-Q of Implant Sciences Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 16, 2016


/s/ William J. McGann
William J. McGann
Chief Executive Officer
(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION

I, Roger P. Deschenes, hereby certify that:

I have reviewed this Quarterly Report on Form 10-Q of Implant Sciences Corporation;

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including our consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.


Date: February 16, 2016
/s/ Roger P. Deschenes
Roger P. Deschenes Vice President, Finance and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANESOXLEY ACT OF 2002

In connection with the Annual Report of Implant Sciences Corporation, a Massachusetts corporation (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William J. McGann, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


	/s/ William J. McGann
	William J. McGann
	Chief Executive Officer
Date: February 16, 2016

This certification accompanies each report of the Company on Form 10-Q and Form 10-K pursuant to §906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by us for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by §906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or our staff upon request.

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANESOXLEY ACT OF 2002

In connection with the Annual Report of Implant Sciences Corporation, a Massachusetts corporation (the “Company”) on Form 10-Q for the fiscal quarter ended December 31, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roger P. Deschenes, Vice President, Finance and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


	/s/ Roger P. Deschenes
	Roger P. Deschenes
	Vice President, Finance and Chief Financial Officer
Date: February 16, 2016

A signed original of this written statement required by §906 has been provided to us and will be retained by us and furnished to the Securities and Exchange Commission or our staff upon request.

Document and Entity Information - USD ($)	6 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2015	Feb. 05, 2016
Document and Entity Information:
Entity Registrant Name	Implant Sciences Corporation
Document Type	10-Q
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Entity Central Index Key	0001068874
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		78,805,620
Entity Public Float	$ 39,582,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Trading Symbol	imsc

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2015

Jun. 30, 2015

Current assets:

Cash and cash equivalents

$ 776

$ 1,985

Restricted cash and investments

367

Accounts receivable-trade, net

6,116

^[1]

872

^[2]

Inventories, net

6,723

5,244

Prepaid expenses and other current assets

491

946

Total current assets

14,473

9,414

Property and equipment, net

841

880

Other non-current assets

Total assets

15,412

10,392

Current liabilities:

Senior secured promissory note

21,000

Senior secured convertible promissory notes

27,184

^[3],[4]

27,184

^[5]

Line of credit

16,862

16,662

Current maturities of obligations under capital lease

Accrued expenses

24,759

17,080

Accounts payable

4,797

2,855

Deferred revenue

1,466

3,454

Total current liabilities

96,094

88,280

Long-term liabilities:

Long-term obligations under capital lease, net of current maturities

Accrued liabilities other - long-term

Deferred revenue, net of current

355

221

Total long-term liabilities

370

289

Total liabilities

$ 96,464

$ 88,569

Commitments and contingencies

Stockholders' deficit:

Common stock

$ 79

^[6]

$ 75

^[7]

Preferred stock

^[8]

^[9]

Series G, H, I and J Convertible Preferred Stock

^[10]

^[11]

Additional paid-in capital

$ 113,566

$ 112,613

Accumulated deficit

(193,653)

(189,429)

Deferred compensation

(993)

(1,366)

Other comprehensive income

Treasury stock

(73)

^[12]

(73)

^[13]

Total stockholders' deficit

(81,052)

(78,177)

Total liabilities and stockholders' deficit

$ 15,412

$ 10,392

[1]	Allowance for doubtful accounts of $5 at December 31, 2015.
[2]	Allowance for doubtful accounts of $47 at June 30, 2015.
[3]	Senior secured convertible promissory notes (the "Note") as of December 31, 2015 composed of i) first Note of $3,184; ii) second Note of $12,000;and, iii) third Note of $12,000.
[4]	Senior secured convertible promissory notes (the "Note") as of September 30, 2015 composed of i) first Note of $3,184; ii) second Note of $12,000;and, iii) third Note of $12,000.
[5]	Senior secured convertible promissory notes (the "Note") as of June 30, 2015 composed of i) first Note of $3,184; ii) second Note of $12,000; and iii) third Note of $12,000.
[6]	$0.001 par value; 200,000,000 shares authorized; 78,699,165 issued and 78,688,620 outstanding at December 31, 2015.
[7]	$0.001 par value; 200,000,000 shares authorized; 75,113,665 issued and 75,103,120 outstanding at June 30, 2015.
[8]	no stated value; 5,000,000 shares authorized at December 31, 2015.
[9]	no stated value; 5,000,000 shares authorized at June 30, 2015.
[10]	no par value; Series G- 650,000 shares authorized, Series H and I - 15,000 and 15,000 shares authorized, respectively; Series J - 6,000 shares authorized; Series G, H, I and J - 0 shares issued and outstanding at December 31, 2015.
[11]	no par value; Series G - 650,000 shares authorized, Series H and I - 15,000 and 15,000 shares authorized, respectively; Series J - 6,000 shares authorized; Series G, H, I and J - 0 shares issued and outstanding at June 30, 2015.
[12]	10,545 common shares, at cost, at December 31, 2015.
[13]	10,545 common shares, at cost, at June 30, 2015.

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Income Statement
Revenues	$ 10,292	$ 2,141	$ 24,685	$ 4,010
Cost of revenues	6,439	1,777	14,575	3,028
Gross margin	3,853	364	10,110	982
Operating expenses:
Research and development	901	1,288	1,984	2,572
Selling, general and administrative	3,718	3,195	7,256	5,870
Total operating expenses	4,619	4,483	9,240	8,442
Loss from operations	(766)	(4,119)	870	(7,460)
Other income (expense), net:
Interest expense	(2,547)	(2,125)	(5,094)	(4,159)
Total other income (expense), net	(2,547)	(2,125)	(5,094)	(4,159)
Net loss	$ (3,313)	$ (6,244)	$ (4,224)	$ (11,619)
Net loss per share, basic and diluted	$ (0.04)	$ (0.09)	$ (0.05)	$ (0.17)
Weighted average shares used in computing net loss per common share, basic	78,528,620	70,938,120	77,367,787	67,842,872
Weighted average shares used in computing net loss per common share, diluted	78,528,620	70,938,120	77,367,787	67,842,872

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (4,224)	$ (11,619)
Adjustments to reconcile net loss to net cash flows:
Depreciation and amortization	104	81
Bad debt expense (recoveries)	(7)	46
Stock-based compensation expense	668	1,227
Warrants issued to non-employees	43	241
Common stock issued to consultants	331	68
Changes in assets and liabilities:
(Increase) decrease in accounts receivable	(5,237)	(416)
(Increase) decrease in inventories	(1,479)	170
(Increase) decrease in prepaid expenses and other current assets	455	37
Increase (decrease) in accounts payable	1,942	(134)
Increase (decrease) in accrued expenses	7,885	3,125
Increase (decrease) in deferred revenue	(1,854)	1,279
Net cash used in operating activities	(1,373)	(5,895)
Cash flows from investing activities:
Purchases of property and equipment	(65)	(314)
Net cash (used in) provided by investing activities	(65)	(314)
Cash flows from financing activities:
Proceeds from common stock issued in connection with exercise of stock options	34	261
Principal repayments of long-term debt and capital lease obligations	(24)	(23)
Net borrowings on line of credit	200	5,605
Net cash provided by financing activities	210	5,843
Effect of exchange rate changes on cash and cash equivalents	19	1
Net change in cash and cash equivalents	(1,209)	(365)
Cash and cash equivalents at beginning of period	1,985	391
Cash and cash equivalents at end of period	776	26
Supplemental Disclosure of Cash Flow Information:
Interest paid	5	1,619
Non-cash Investing and Financing Activity:
Conversions of senior secured convertible promissory note and interest to common shares	245	604
Common stock issued for consulting services	$ 331	$ 68

Description of Business, Liquidity and Going Concern

6 Months Ended

Dec. 31, 2015

Notes

Description of Business, Liquidity and Going Concern

1. Description of Business, Liquidity and Going Concern

Liquidity, Going Concern and Management’s Plans

Despite our current sales, expense and cash flow projections and $3,084,000 in cash available from our line of credit with DMRJ, at February 5, 2016, to fund our operations and continue the development, commercialization and marketing of our products will require that we extend our note agreements with DMRJ, BAM and Monstant. There can be no assurance that DMRJ will continue to make advances under our revolving line of credit. Our failure to achieve our projections and/or obtain sufficient additional capital on acceptable terms would have a material adverse effect on our liquidity and operations and could require us to file for protection under bankruptcy laws.

On September 24, 2015, Montsant converted $245,000 of the accrued interest owed by us under a promissory note into 3,062,500 shares of our common stock, at an adjusted conversion price of $0.08 per share.

These conditions raise substantial doubt as to our ability to continue as a going concern.

Interim Financial Statements and Basis of Presentation

6 Months Ended

Dec. 31, 2015

Notes

Interim Financial Statements and Basis of Presentation

2.Interim Financial Statements and Basis of Presentation

Principles of Consolidation

Accounting Principles

The information contained in this Form 10-Q should be read in conjunction with our audited financial statements, included in our Form 10-K, as of and for the year ended June 30, 2015.

Use of Accounting Estimates

Significant accounting policies are described in Note 2 to the consolidated financial statements included in Item 7 of our Form 10-K for the fiscal year ended June 30, 2015.

Foreign Currency Translation

Recent Accounting Pronouncements

Fair Value Measurement

6 Months Ended

Dec. 31, 2015

Notes

Fair Value Measurement

3. Fair Value Measurement

Level 1 inputs to the valuation methodology are based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 inputs to the valuation methodology are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The following table provides the non-recurring fair value measurements of assets and liabilities as of December 31, 2015:

		Fair Value Measurements as of December 31, 2015
Description (In thousands)	Carrying Value at December 31, 2015	Quoted Prices in Active Markets for Identical Asset Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3
Certificates of deposit	$ 312	$ 312	$ -	$ -
Senior secured promissory note	21,000	-	-	21,000
Senior secured convertible promissory note	27,184	-	-	27,184
Line of credit - DMRJ	16,862	-	-	16,862

The following table provides the non-recurring fair value measurements of assets and liabilities as of June 30, 2015:

		Fair Value Measurements as of June 30, 2015
Description (In thousands)	Carrying Value at June 30, 2015	Quoted Prices in Active Markets for Identical Asset Level 1	Significant Other Observable Inputs Level 2	Significant Unobservable Inputs Level 3
Certificates of deposit	$ 312	$ 312	$ -	$ -
Senior secured promissory note	21,000	-	-	21,000
Senior secured convertible promissory note	27,184	-	-	27,184
Line of credit - DMRJ	16,662	-	-	16,662

Restricted Cash and Investments - Current and Long-term

6 Months Ended

Dec. 31, 2015

Notes

Restricted Cash and Investments - Current and Long-term

4. Restricted Cash and Investments

As of December 31, 2015 and June 30, 2015, we had restricted cash and investments, with maturities of less than one year, of $367,000. Restricted cash and investments consisted of the following:

(In thousands)	December 31, 2015	June 30, 2015
Current assets
Certificates of deposit	$ 312	$ 312
Cash maintained to secure corporate credit card	55	55
Total	$ 367	$ 367

Stock Based Compensation

6 Months Ended

Dec. 31, 2015

Notes

Stock Based Compensation

5. Stock Based Compensation

For the three months ended December 31, 2015 and 2014, our consolidated statements of operations and comprehensive loss include $326,000 and $535,000, respectively, of compensation costs and no income tax benefit related to our stock-based compensation arrangements for employee and non-employee director awards. For the six months ended December 31, 2015 and 2014, our condensed consolidated statements of operations and comprehensive loss include $668,000 and $1,227,000, respectively, of compensation costs and no income tax benefit related to our stock-based compensation arrangements for employee and non-employee director awards, as follows:

(In thousands)	Three Months Ended December 31, 2015	Three Months Ended December 31, 2014	Six Months Ended December 31, 2015	Six Months Ended December 31, 2014
Cost of revenues	$ 31	$ 53	$ 61	$ 101
Research and development	46	120	130	242
Selling, general and administrative	249	362	477	884
Total	$ 326	$ 535	$ 668	$ 1,227

As of December 31, 2015, the total amount of unrecognized stock-based compensation expense was approximately $1,741,000, which will be recognized over a weighted average period of 1.66 years.

Related Party Transactions

6 Months Ended

Dec. 31, 2015

Notes

Related Party Transactions

6. Related Party Transactions

Prepaid Expenses and Other Current Assets

6 Months Ended

Dec. 31, 2015

Notes

Prepaid Expenses and Other Current Assets

7.Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(In thousands)	December 31, 2015	June 30, 2015
Inventory deposits	$ 280	$ 677
Insurance	58	87
Bank fees	6	14
Other prepaid expenses	147	168
Total	$ 491	$ 946

Inventories, Net

6 Months Ended

Dec. 31, 2015

Notes

Inventories, Net

8. Inventories, net

(In thousands)	December 31, 2015	June 30, 2015
Raw materials	$ 3,895	$ 3,283
Work in progress	1,418	1,455
Finished goods	1,410	506
Total	$ 6,723	$ 5,244

As of December 31, 2015 and June 30, 2015, our reserves for excess and slow-moving inventories were $213,000 and $218,000, respectively.

Property and Equipment, net

6 Months Ended

Dec. 31, 2015

Notes

Property and Equipment, net

9.Property and Equipment, net

Property and equipment consist of the following:

(In thousands)	December 31, 2015	June 30, 2015
Machinery and equipment	$ 553	$ 533
Computers and software	432	415
Furniture and fixtures	91	83
Leasehold improvements	173	159
Equipment under capital lease	159	157
Construction in progress	342	342
Sub-total	1,750	1,689
Less: accumulated depreciation and amortization	909	809
Total	$ 841	$ 880

For the three months ended December 31, 2015 and 2014, depreciation expense was approximately $50,000 and $40,000, respectively.

For the six months ended December 31, 2015 and 2014, depreciation expense was approximately $104,000 and $81,000, respectively.

Accrued Expenses-Current and Long-Term

6 Months Ended

Dec. 31, 2015

Notes

Accrued Expenses-Current and Long-Term

10. Accrued Expenses – Current and Long-Term

Accrued expenses consist of the following:

(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Accrued interest	$ 18,108	$ 13,264
Accrued compensation and benefits	3,299	1,774
Accrued warranty costs	1,337	556
Accrued legal and accounting	52	257
Accrued taxes	146	74
Other accrued liabilities	1,817	1,155
Total	$ 24,759	$ 17,080

Long-term liabilities
Accrued compensation and benefits	$ -	$ 48
	$ -	$ 48

Deferred Revenues-Current and Long-Term

6 Months Ended

Dec. 31, 2015

Notes

Deferred Revenues-Current and Long-Term

11. Deferred Revenues – Current and Long-Term

(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Customer advance payments	$ 1,033	$ 3,121

(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Extended warranty service agreements	$ 433	$ 333

	December 31, 2015	June 30, 2015
Long-term liabilities
Extended warranty service agreements	$ 355	$ 221

Earnings Per Share

6 Months Ended

Dec. 31, 2015

Notes

Earnings Per Share

12. Earnings Per Share

(In thousands, except share and per share amounts)	Three Months Ended December 31, 2015	Three Months Ended December 31, 2014	Six Months Ended December 31, 2015	Six Months Ended December 31, 2014
Basic and diluted loss per share:
Numerator:
Net loss	$ (3,313)	$ (6,244)	$ (4,224)	$ (11,619)
Denominator:
Weighted average shares	78,528,620	70,938,120	77,367,787	67,842,872
Basic and diluted loss per share	$ (0.04)	$ (0.09)	$ (0.05)	$ (0.17)

Common stock equivalents excluded from the diluted earnings per share calculation for the three and six months ended December 31, 2015 and 2014, were as follows:

	Three Months Ended December 31, 2015	Three Months Ended December 31, 2014	Six Months Ended December 31, 2015	Six Months Ended December 31, 2014
Common stock equivalents excluded
Stock options	556,561	2,141,637	686,859	2,406,659
Warrants	-	579,207	32,396	689,052
Convertible debt	39,800,000	60,978,666	39,800,000	60,978,666
	40,356,561	63,699,510	40,519,255	64,074,377

Long-Term Debt and Credit Arrangements

6 Months Ended

Dec. 31, 2015

Notes

Long-Term Debt and Credit Arrangements

13. Long-Term Debt and Credit Arrangements

Term Debt and Revolving Credit Facility with DMRJ Group, LLC and Term Debt with Montsant Partners, LLC

The note contains restrictions and financial covenants including: (i) restrictions against declaring or paying dividends or making any distributions; against creating, assuming or incurring any liens or indebtedness; against creating, assuming or incurring any indebtedness; against merging or consolidating with any other company, provided, however, that a merger or consolidation is permitted if we are the surviving entity; against the sale, assignment, transfer or lease of our assets, other than in the ordinary course of business and excluding inventory and certain asset sales expressly permitted by the note purchase agreement; against making investments in any company, extending credit or loans, or purchasing stock or other ownership interest of any company; and (ii) covenants that we have authorized or reserved for the purpose of issuance, 150% of the aggregate number of shares of our common stock issuable upon exercise of the warrant; that we maintain a minimum cash balance of at least $500,000; that the aggregate dollar amount of all accounts payable be no more than 100 days past due; and that we maintain a current ratio, defined as current assets divided by current liabilities, of no less than 0.60 to 1.00.

In October 2011, we further amended each of our credit instruments with DMRJ, to eliminate the obligation to repay any portion of our outstanding indebtedness to DMRJ by December 31, 2011.

In February 2012, we amended each of our credit instruments with DMRJ, to extend the maturity of all of our indebtedness to DMRJ to September 30, 2012.

Each share of Series H Preferred Stock will be convertible, at the option of the holder, into that number of shares of Common Stock as is determined by (i) dividing the Series H Original Issue Price by the Series H Conversion Price (as defined below) in effect at the time of conversion and (ii) multiply the result by 1,000. The “Series H Conversion Price” will initially be equal to $1,090, and is subject to adjustment in the event that (a) we issue additional shares of Common Stock as a dividend or other distribution on outstanding shares of Common Stock, (b) there is a split or subdivision of outstanding shares of Common Stock, or (c) there is a combination or reverse stock split of outstanding shares of Common Stock into a smaller number of shares of Common Stock. Assuming no adjustments to the Series H Original Issue Price or the Series H Conversion Price, the New Note will be convertible indirectly, at DMRJ’s option, into shares of Common Stock at an effective conversion price of $1.09 per share, which represents a discount of approximately 20% from the daily volume weighted average price of the Common Stock over the 20 trading days preceding the date of the amendment.

On February 28, 2013, we further amended each of our credit instruments with DMRJ. Pursuant to those amendments:

· the maturity of all of our indebtedness to DMRJ was extended from March 31, 2013 to March 31, 2014;

· DMRJ waived our compliance with certain financial covenants in each of our promissory notes and all related credit agreements through the new maturity date;

· DMRJ’s option to require us to repurchase any or all of the shares of Series H Convertible Preferred Stock ) which may be issued upon conversion of the September 2012 Note was eliminated;

· we issued to DMRJ a third senior secured convertible promissory note dated February 28, 2013, in the aggregate principal amount of $12,000,000. Payment for the February 2013 Note was made by the cancellation of $12,000,000 of principal of the outstanding indebtedness under our credit agreement;

· DMRJ acquired the option to convert the amended and restated senior secured convertible promissory note dated March 12, 2012 (the “March 2012 Note”) into shares of Series J Convertible Preferred Stock in lieu of shares of Common Stock; and

· the March 2012 Note and the September 2012 Note were amended to permit us to prepay any or all of our indebtedness thereunder on 30 days prior notice.

The holders of Series J Preferred Stock will be entitled to participate on an “as converted” basis in all dividends or distributions declared or paid on our Common Stock.

As of December 31, 2015, there were no shares of Series H Preferred Stock, Series I Preferred Stock or Series J Preferred Stock outstanding.

On November 14, 2013, we amended each of our credit agreements with DMRJ to extend the maturity date of all of our indebtedness to DMRJ from March 31, 2014 to September 30, 2014.

On March 19, 2014, we further amended each of our credit instruments with DMRJ. Pursuant to those amendments:

· the maturity of all of our indebtedness to DMRJ was extended from September 30, 2014 to March 31, 2015;

· DMRJ waived our compliance with certain financial covenants in each of our promissory notes and all related credit agreements through the new maturity date;

· DMRJ consented to the execution and delivery of the note purchase agreement with BAM and agreed to waive all prepayment limitations and prepayment notice requirements set forth in any of the credit documents to which DMRJ and the company are parties with respect to the repayments and prepayments financed by the sale of the notes.

· DMRJ agreed to subordinate its first position security interest in all of our assets to BAM.

Term Debt with BAM

On March 19, 2014, we entered into a note purchase agreement with a group of institutional investors and BAM Administrative Services LLC (“BAM”), an administrative agent for the investors, pursuant to which we issued senior secured promissory notes in the aggregate principal amount of $20,000,000. The notes bear interest at 15% per annum and mature on March 31, 2015. The proceeds from the sale of the notes were used to repay (i) $17,624,000 of our outstanding indebtedness to DMRJ under the amended and restated revolving promissory note dated September 29, 2011 (ii) $1,809,000 of interest outstanding under the amended and restated promissory note and (iii) $567,000 of interest outstanding under our senior secured convertible promissory note dated September 5, 2012.

Stockholders' Deficit

6 Months Ended

Dec. 31, 2015

Notes

Stockholders' Deficit

14.Stockholders’ Deficit

Common Shares Authorized

Common Stock Options and Stock Purchase Warrants

Common Stock Options

As of December 31, 2015, there were options outstanding to purchase 21,076,651 shares of our common stock at exercise prices ranging from $0.08 to $2.30.

Stock Purchase Warrants and Stock Issuances

Income Taxes

6 Months Ended

Dec. 31, 2015

Notes

Income Taxes

15.Income Taxes

(In thousands)

Net Operating Losses

Investment AMT & Research Credits

Expiration Dates

Federal

$ 107,818

$ 1,455

2022 to 2035

State

$ 74,879

$ 983

2016 to 2035

Potential 382 Limitation

Tax years 2012 through 2015 are subject to examination by the federal and state taxing authorities. There are no income tax examinations currently in process.

Commitments and Contingencies

6 Months Ended

Dec. 31, 2015

Notes

Commitments and Contingencies

16.Commitments and Contingencies

License Agreements

Financial Information by Segment

6 Months Ended

Dec. 31, 2015

Notes

Financial Information by Segment

17. Financial Information By Segment

Legal

6 Months Ended

Dec. 31, 2015

Notes

Legal

18.Legal

Subsequent Events

6 Months Ended

Dec. 31, 2015

Notes

Subsequent Events

19.Subsequent Events

Interim Financial Statements and Basis of Presentation: Principles of Consolidation (Policies)

6 Months Ended

Dec. 31, 2015

Policies

Principles of Consolidation

Principles of Consolidation

Interim Financial Statements and Basis of Presentation: Basis of Accounting (Policies)

6 Months Ended

Dec. 31, 2015

Policies

Basis of Accounting

Accounting Principles

The information contained in this Form 10-Q should be read in conjunction with our audited financial statements, included in our Form 10-K, as of and for the year ended June 30, 2015.

Interim Financial Statements and Basis of Presentation: Use of Accounting Estimates (Policies)

6 Months Ended

Dec. 31, 2015

Policies

Use of Accounting Estimates

Use of Accounting Estimates

Interim Financial Statements and Basis of Presentation: Significant Accounting Policies (Policies)	6 Months Ended
	Dec. 31, 2015
Policies
Significant Accounting Policies	Significant accounting policies are described in Note 2 to the consolidated financial statements included in Item 7 of our Form 10-K for the fiscal year ended June 30, 2015.

Interim Financial Statements and Basis of Presentation: Foreign Currency Translation (Policies)

6 Months Ended

Dec. 31, 2015

Policies

Foreign Currency Translation

Foreign Currency Translation

Fair Value Measurement: Fair Value Measurement Policy (Policies)

6 Months Ended

Dec. 31, 2015

Policies

Fair Value Measurement Policy

Level 1 inputs to the valuation methodology are based on quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 inputs to the valuation methodology are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

Deferred Revenues-Current and Long-Term: Deferred Revenue Recognition Policy. (Policies)	6 Months Ended
	Dec. 31, 2015
Policies
Deferred Revenue Recognition Policy.	Deferred revenues are recorded when we receive payments for product or services for which we have not yet completed our obligation to deliver product or have not completed services required by the contractual agreements.

Restricted Cash and Investments - Current and Long-term: Schedule of Restricted Cash and Cash Equivalents (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Restricted Cash and Cash Equivalents

(In thousands)	December 31, 2015	June 30, 2015
Current assets
Certificates of deposit	$ 312	$ 312
Cash maintained to secure corporate credit card	55	55
Total	$ 367	$ 367

Stock Based Compensation: Schedule of Stock-based Compensation Allocation (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Stock-based Compensation Allocation

(In thousands)	Three Months Ended December 31, 2015	Three Months Ended December 31, 2014	Six Months Ended December 31, 2015	Six Months Ended December 31, 2014
Cost of revenues	$ 31	$ 53	$ 61	$ 101
Research and development	46	120	130	242
Selling, general and administrative	249	362	477	884
Total	$ 326	$ 535	$ 668	$ 1,227

Prepaid Expenses and Other Current Assets: Schedule of Prepaid and Other Current Assets (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Prepaid and Other Current Assets

(In thousands)	December 31, 2015	June 30, 2015
Inventory deposits	$ 280	$ 677
Insurance	58	87
Bank fees	6	14
Other prepaid expenses	147	168
Total	$ 491	$ 946

Inventories, Net: Schedule of Inventories, net (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Inventories, net

(In thousands)	December 31, 2015	June 30, 2015
Raw materials	$ 3,895	$ 3,283
Work in progress	1,418	1,455
Finished goods	1,410	506
Total	$ 6,723	$ 5,244

Property and Equipment, net: Schedule of Property and Equipment (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Property and Equipment

(In thousands)	December 31, 2015	June 30, 2015
Machinery and equipment	$ 553	$ 533
Computers and software	432	415
Furniture and fixtures	91	83
Leasehold improvements	173	159
Equipment under capital lease	159	157
Construction in progress	342	342
Sub-total	1,750	1,689
Less: accumulated depreciation and amortization	909	809
Total	$ 841	$ 880

Accrued Expenses-Current and Long-Term: Schedule of Accrued Expenses (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Accrued Expenses

(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Accrued interest	$ 18,108	$ 13,264
Accrued compensation and benefits	3,299	1,774
Accrued warranty costs	1,337	556
Accrued legal and accounting	52	257
Accrued taxes	146	74
Other accrued liabilities	1,817	1,155
Total	$ 24,759	$ 17,080

Long-term liabilities
Accrued compensation and benefits	$ -	$ 48
	$ -	$ 48

Deferred Revenues-Current and Long-Term: Schedule of Customer Advance Payment (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Customer Advance Payment

(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Customer advance payments	$ 1,033	$ 3,121

Deferred Revenues-Current and Long-Term: Schedule of Extended Warranty Service Agreements (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Extended Warranty Service Agreements

(In thousands)	December 31, 2015	June 30, 2015
Current liabilities
Extended warranty service agreements	$ 433	$ 333

	December 31, 2015	June 30, 2015
Long-term liabilities
Extended warranty service agreements	$ 355	$ 221

Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Earnings Per Share, Basic and Diluted

(In thousands, except share and per share amounts)	Three Months Ended December 31, 2015	Three Months Ended December 31, 2014	Six Months Ended December 31, 2015	Six Months Ended December 31, 2014
Basic and diluted loss per share:
Numerator:
Net loss	$ (3,313)	$ (6,244)	$ (4,224)	$ (11,619)
Denominator:
Weighted average shares	78,528,620	70,938,120	77,367,787	67,842,872
Basic and diluted loss per share	$ (0.04)	$ (0.09)	$ (0.05)	$ (0.17)

Earnings Per Share: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

Common stock equivalents excluded from the diluted earnings per share calculation for the three and six months ended December 31, 2015 and 2014, were as follows:

	Three Months Ended December 31, 2015	Three Months Ended December 31, 2014	Six Months Ended December 31, 2015	Six Months Ended December 31, 2014
Common stock equivalents excluded
Stock options	556,561	2,141,637	686,859	2,406,659
Warrants	-	579,207	32,396	689,052
Convertible debt	39,800,000	60,978,666	39,800,000	60,978,666
	40,356,561	63,699,510	40,519,255	64,074,377

Income Taxes: Summary of Tax Credit Carryforwards (Tables)

6 Months Ended

Dec. 31, 2015

Tables/Schedules

Summary of Tax Credit Carryforwards

(In thousands)

Net Operating Losses

Investment AMT & Research Credits

Expiration Dates

Federal

$ 107,818

$ 1,455

2022 to 2035

State

$ 74,879

$ 983

2016 to 2035

Fair Value Measurement (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
Senior Notes
Investment Owned, at Fair Value	$ 21,000	$ 21,000
Loans Payable
Investment Owned, at Fair Value	27,184	27,184
Domestic Line of Credit
Investment Owned, at Fair Value	16,862	16,662
Certificates of Deposit
Investment Owned, at Fair Value	312	312
Fair Value, Inputs, Level 1 \| Certificates of Deposit
Investment Owned, at Fair Value	312	312
Fair Value, Inputs, Level 3 \| Senior Notes
Investment Owned, at Fair Value	21,000	21,000
Fair Value, Inputs, Level 3 \| Loans Payable
Investment Owned, at Fair Value	27,184	27,184
Fair Value, Inputs, Level 3 \| Domestic Line of Credit
Investment Owned, at Fair Value	$ 16,862	$ 16,662

Restricted Cash and Investments - Current and Long-term (Details) - USD ($)	Dec. 31, 2015	Jun. 30, 2015
Details
Restricted Cash and Investments, Current	$ 367,000	$ 367,000

Restricted Cash and Investments - Current and Long-term: Schedule of Restricted Cash and Cash Equivalents (Details) - USD ($)	Dec. 31, 2015	Jun. 30, 2015
Details
Certificates of Deposit, at Carrying Value	$ 312	$ 312
Restricted Cash and Cash Equivalents, Current	$ 55	$ 55

Inventories, Net: Schedule of Inventories, net (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
Details
Inventory, Raw Materials, Net of Reserves	$ 3,895	$ 3,283
Inventory, Work in Process, Net of Reserves	1,418	1,455
Inventory, Finished Goods, Net of Reserves	$ 1,410	$ 506

Inventories, Net (Details) - USD ($)	Dec. 31, 2015	Jun. 30, 2015
Details
Inventory Valuation Reserves	$ 213,000	$ 218,000

Property and Equipment, net: Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
Details
Machinery and Equipment, Gross	$ 553	$ 533
Computers and software	432	415
Furniture and Fixtures, Gross	91	83
Leasehold Improvements, Gross	173	159
Capital Leases, Lessee Balance Sheet, Assets by Major Class, Other Property, Plant, and Equipment, Gross	159	157
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	$ 909	$ 809

Property and Equipment, net (Details) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment, net (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Details
Depreciation	$ 50,000	$ 40,000	$ 104,000	$ 81,000

Deferred Revenues-Current and Long-Term: Schedule of Customer Advance Payment (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
Details
Deferred revenue	$ 1,466	$ 3,454

Deferred Revenues-Current and Long-Term: Schedule of Extended Warranty Service Agreements (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Jun. 30, 2015
Details
Extended Product Warranty Accrual, Current	$ 433	$ 333
Extended Product Warranty Accrual, Noncurrent	$ 355	$ 221

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Your Recent History